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1. Introduction 
1.1.  Pulmonary alveolus  
The lung is a specialized organ for gas exchange and represents the largest epithelial surface 
of the body in contact with the external environment. It is consisted of the two functionally 
and structurally distinct regions known as upper (or proximal, conducting) and lower (or 
distal) respiratory tracts. The upper respiratory tract (nose, pharynx) serves to filter, warm and 
humidify inhaled air, thus protecting the respiratory membranes of the lower tract from 
damage. The trachea connects the upper to the lower respiratory tract which further divides 
into left and right main bronchi. The main bronchi are often considered as the start of the 
lower respiratory tract, functioning in the conduction of inspired air through to the gas 
exchange region of the alveoli. Further bifurcations of the bronchi lead to formation of small 
bronchi, bronchioles and terminal bronchioles. The far distal respiratory zone ultimately 
comprises the respiratory bronchioles, alveolar ducts, and the alveoli themselves (1). 
The alveoli, or air sacs, are organized as clusters continuous with the alveolar ducts. Each 
pulmonary alveolus is surrounded by many blood capillaries constituting an extensive air–
blood interface, comprised mainly of alveolar epithelium and pulmonary capillary 
endothelium, which allows an optimal gas-diffusion across the respiratory membrane. The 
alveolar epithelial surface is covered with a film of surfactant that lowers the surface tension 
in the lungs and is essential when the alveolar sacs are to expand during inspiration (1, 2). 
The interstitium lying between the alveolar epithelium and pulmonary capillary endothelium 
is made up of several different cell types (fibroblasts, mast cells, myofibroblasts and dendritic 
cells) and basement membrane components (1, 3). The alveolar wall itself is consisted of two 
main cell types: alveolar epithelial cells and resident alveolar macrophages (Fig. 1). 
1.1.1.  Alveolar Epithelial Cells (AEC) 
Alveolar epithelium is comprised of two morphologically and functionally distinct cell types, 
alveolar epithelial cells type I (AEC I) and type II (AEC II) (Fig. 1). Highly flattened AEC I 
cover 95% of the internal alveolar surface area, whereas cuboidal AEC II cover the remaining 
5%. 
A major function of AEC II is the synthesis of surfactant (surface active agent) and its 
subsequent release from the intracellular storage granules (lamellar bodies) by exocytosis 
upon different stimuli (4). Its primary role is to provide efficient ventilation by regulating 
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surface tension according to the alveolar size. Surfactant is composed of 90% phospholipids 
and 10% proteins (surfactant proteins (SP) -A, B, C and D). Although a few other lung cells 
may produce SP-A, SP-B and SP-D, AEC II are the only pulmonary cells known to produce 
all surfactant components. SP-C is known to be produced only by AEC II (5-7). 
Studies investigating the mechanisms of pulmonary oedema clearance revealed that the 
alveolar barrier is not just a tight epithelium but it also participates in the active ion and solute 
transport across the epithelial-endothelial barrier (8). Hence, AEC II are known to possess 
membrane bound water channels and ion pumps, enabling them to form a very thin aqueous 
film (hypophase), which serves as an environment for extracellular biochemical reactions as 
well as a “medium” for intra-alveolar cells such as resident alveolar macrophages and enables 
paracrine cellular crosstalk via soluble mediators (6, 9, 10). 
AEC II have been shown to have unlimited potential for proliferation and self-renewal, and 
are therefore described as the stem cell of the alveolar epithelium (6, 11-14). Hence, the 
following concept for AEC II as the alveolar stem cell, as well as the process of transition of 
AEC II into AEC I following injury, was postulated (15): upon lung injury the nearest AEC II 
proliferate and, if necessary, differentiate into squamous AEC I, which are terminally 
differentiated and thus incapable of division. However, only a fraction of the daughter cells 
differentiate; the remaining part is believed to retain type II phenotype thereby replenishing 
the original stem cell population. Transition into AEC I may be preceded by division of AEC 
II (differentiation) or may occur without any mitotic events (trans-differentiation). The in vivo 
evidence for the process of differentiation/trans-differentiation are obscure; however 
numerous in vitro studies supported this concept, as described in details in the next section 
(1.1.1.1 AEC in vitro culture). Of note, emerging evidence suggests the possibility that not all 
AEC II in the lung, but a certain subpopulation has the capacity to repopulate the injured 
epithelium (15-17).  
AEC I compose the largest part of the peripheral lung and due to their morphology are highly 
specialized cells for gas exchange. In contrast to AEC II, the biology of AEC I has been 
largely unexplored, because until recently it has been impossible to isolate these fragile cells 
from the lungs and to culture them in vitro. AEC I have numerous cellular extensions which 
occasionally may form the epithelium of more than one alveolus, thereby building a complex 
architecture which partially explains their greater susceptibility to injury (14, 18, 19).  
Another difficulty accompanying the AEC I research is the deficiency of specific cellular 
markers for these cells. T1-α (podoplanin, gp 38, RTI 40) has been described as the first and 
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most reliable marker for AEC I and its expression in the adult lung has been restricted to type 
I cells (14, 18, 20).  
AEC I expression of aquaporin 5 (Aqp-5) (14, 21), a member of the water channels family, 
and the phenotype of Aqp-5 knock-out mice indicated that AEC I are competent cells for ion 
and water transport. A recent study (22) clearly evidenced that rat AEC I express Na+, K+ 
channels and cystic fibrosis trans-membrane regulator (CFTR), thereby supporting this 
hypothesis. 
1.1.1.1. AEC in vitro culture 
Primary culture of alveolar epithelial cells, particularly AEC II, is a widely accepted model 
for studying their biology. According to the common paradigm, AEC II over several days of 
in vitro culture differentiate/ trans-differentiate into AEC I-like cells, a process which 
resembles the AEC II in vivo differentiation. This concept was postulated in 1992 in the study 
from Shannon et al. (23) showing that rat AEC II cultured on fibroblast feeder layers lose 
their lamellar bodies and acquire specific AEC I morphology. Similarly, Danto et al. provided 
evidence that differentiated AEC II grown on collagen gels acquire additional AEC I specific 
antigens. 
Over the next 15 years numerous studies further developed these in vitro concepts; the 
majority of them emphasizing the influence of the culture conditions on AEC differentiation. 
Hence, keratinocyte growth factor (KGF) prevents increase of T1-α expression in rat AEC II 
cultures (24), thereby promoting in vitro maintenance of the type II phenotype. Likewise, the 
matrigel:collagen culture substrate enables phenotype preservation of murine and human 
alveolar epithelial type II cells (25, 26).  
Despite the numerous evidence supporting the concept of AEC II to I differentiation, the 
molecular signals underlying these phenotype changes (in vivo and in vitro) remain largely 
unknown. Transforming growth factor-ß1 (TGF-ß1) is the only molecule shown to be 
involved in AEC II to AEC I in vitro differentiation (27), whereas c-Jun N-terminal kinase 
(JNK) has been shown to mediate KGF-induced preservation of AEC II phenotype (28).  
However, given that the isolation of AEC I has been recently established only in rats, and is 
associated with low yields (29), AEC I-like cells differentiated over 5-7 days from AEC II 
remain to be a reliable model of lung alveolar type I epithelial cells.  
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1.1.2.  Resident alveolar macrophages (AMφ) – the sentinel phagocytic cell of the innate 
immune system of the lung 
A large array of microbial products and particles enter the lungs on a daily basis. 
Contaminants larger in size either deposit in the upper respiratory tract or sediment on its 
mucociliary surface, thereby being prevented from further spread into the alveolar space. 
Contaminants smaller then 1 µm, such as bacteria and viral particles, are carried to the 
alveolar surface where they interact with local innate immune system components - alveolar 
fluids (e.g. IgA, complement, surfactants) and resident leukocytes. Normally, resident alveolar 
macrophages (AMφ) account for ~ 95% of airspace leukocytes, with 1 to 4% lymphocytes and 
only about 1% neutrophils, thereby representing the major sentinel phagocytic cell of the 
innate immune system of the lungs (30). Resident alveolar macrophages are known to form 
the first line of defence against bacteria invading the alveolar air space. They are distributed at 
the air-tissue interface of the alveolar space and closely adhere to alveolar epithelial cells. 
Though AMφ are avidly phagocytic and ingest large numbers of particles, they are relatively 
inert in terms of triggering inflammatory responses because their primary role is to keep 
airspaces quiescent. However, when the microbial challenge is too numerous or too virulent to 
be contained by macrophages alone, AMφ mount an innate immune response and local 
inflammation (30, 31).  
 
1.2.  Pathogen-induced acute lung injury  
Acute lung injury (ALI) and its severest form acute respiratory distress syndrome (ARDS) are 
definitions of acute respiratory failure, caused by diffuse damage to the pulmonary 
parenchyma within hours to days by a variety of local or systemic insults (32). Increased 
alveolar-capillary membrane permeability due to endothelial and epithelial disruption and/or 
diffuse inflammatory reaction in the pulmonary parenchyma, was recognized as the common 
end of organ injury and a central feature in all forms of ALI/ARDS (33). Due to the increased 
permeability of the alveolar–capillary barrier, an extensive extravasation of protein-rich fluid 
into the air spaces takes place, which consequently leads to a formation of pulmonary oedema. 
Alveolar epithelial damage in ALI is associated with impaired lung ion/water transport and 
subsequent clearance of the edema fluid, as well as surfactant abnormalities. Moreover, 
disrupted epithelium may result in a septic shock in patients with pneumonia due to 
translocation of pathogens into the blood stream, and finally persistent severe injury without 
organized and sufficient epithelial repair may lead to lung fibrosis (34). 
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Alveolar microbial challenge leads to activation of AMφ and subsequent release of pro-
inflammatory cytokines that are under the control of the transcription factors of the nuclear 
factor-κB family (NF-κB). These cytokines are interleukin (IL)-1β, tumour necrosis factor 
(TNF)-α, IL-6, IL-12, macrophage inhibitory protein (MIP) – 1α. TNF-α and IL-1ß are 
designated as early response cytokines (35) and stimulate production of chemo-attractants 
from epithelial cells, such as macrophage inflammatory protein (MIP)-2 (the most potent 
neutrophil attractant) and CCL2 (monocyte attractant) in mice (31, 36, 37). Furthermore TNF-
α induces up-regulation of adhesion molecules, thereby enhancing neutrophil influx from the 
surrounding blood capillary in the alveolar space. Apart from the production of pro-
inflammatory cytokines, AMφ directly ingest pathogens, and both AMφ and recruited 
neutrophils have receptors for antibodies and complement, so that the coating of 
microorganisms with antibodies, complement, or both, enhances phagocytosis. The engulfed 
microorganisms are subjected to a wide range of toxic intracellular molecules, including 
superoxide anion, hydroxyl radicals, hypochlorous acid, nitric oxide, antimicrobial cationic 
proteins and peptides, and lysozyme. Phagocytes also remove the body's own dead or dying 
cells, thereby preventing further development of the inflammatory reactions at the site of 
injury (38).  
During the later course of inflammation the destroyed AMφ pool in the alveolar space is 
replaced by lung-differentiation of peripheral blood monocytes (“exudate macrophages”, 
ExMφ). ARDS has been associated with high levels of the chemokine CCL2, the major 
monocyte chemoattractant (39). 
AEC are active participants in the inflammatory reaction and respond to the presence of 
microbes by induction of two complementary parts of an innate immune response: 1) 
increased production of antimicrobial agents and 2) induction of a signal network to recruit 
leukocytes (40). Hence SP-A and SP-D act as collectins, opsonize the pathogen and allow 
phagocytosis by AMφ. Furthermore, AEC express a variety of toll-like receptors for pathogen 
recognition and in response to LPS have been shown to produce chemokines and the potent 
antimicrobial peptide human ß-defensin-2 (HBD2) and LPS-neutralizing peptide LL-37 
(cathelicidin) (41, 42). During Influenza virus infection CCL2 is strongly released from 
murine AEC, thereby stimulating remarkable monocyte transmigration across the epithelium. 
(43). 
 Pathogen-induced tissue damage, massive inflammatory responses and dying alveolar cells 
lead to acute lung injury and require ultimate resolution of inflammation to restore normal 
lung function.  
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Figure 1. The Normal Alveolus and the Injured Alveolus in the Acute Phase of Acute Lung 
Injury. Left panel: Healthy alveolus in steady state represents a quiescent environment, composed of 
the following structures: the alveolar wall structured by alveolar epithelial cells (AEC II and AEC I), 
resident alveolar macrophages (AMφ), the alveolar endothelium and the alveolar interstitium. Right 
panel: Following pathogen invasion AMφ are the first cells to respond and secrete TNF-α, which acts 
locally to stimulate production of pro-inflammatory cytokines by AEC such as MIP-2 and CCL2, 
thereby stimulating rapid neutrophil (Neu) influx into the alveolar space, followed by monocyte (Mo) 
recruitment from the surrounding capillaries. Once they reach the alveolar space Mo differentiate into 
macrophages (exudate macrophages, ExMφ). Consequently, the pathogen itself and the massive 
inflammation cause a severe damage to the sensitive endo-epithelial alveolar barrier, which finally 
leads to oedema formation and alveolar flooding. Neu, neutrophils: Mo, monocytes; ExMφ, exudate 
macrophages. 
 
1.3.  Resolution of inflammation 
Reestablishment of the tissue homeostasis (resolution) is a complex and actively regulated 
process that involves all resident alveolar cells (44). 
Neutrophils recruited in the alveolar space after microbial invasion neutralise and eliminate 
the injurious stimuli. This step, though obvious, is perhaps the critical one for acute 
inflammation to resolve. Hence, phagocyte removal of the pathogens, accompanied with 
release of factors that prevent ongoing neutrophil trafficking and oedema formation represent 
the first step in resolution of acute inflammation (45). The second and most important step in 
resolution is disposal of the neutrophils from the site of injury in a controlled and effective 
manner, to protect the alveolus from further harm. Pro-inflammatory arachidonic acid 
products prostaglandin E2 and D2, released from neutrophils upon pathogen phagocytosis, 
stimulate the switch of arachidonic-acid-metabolism into production of the pro-resolution 
lipid mediators lipoxins, resolvins and protectins (44). Recent results indicate that, as 
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inflammation proceeds, neutrophils in exudates stop producing chemoattractants and within 
hours begin to convert arachidonic acid into protective lipoxins (46, 47). Murine macrophages 
generate lipoxins upon engulfment of apoptotic leukocytes (48). Specific lipoxins, resolvins 
and protectins provide potent signals that selectively stop neutrophil infiltration, stimulate 
recruitment of monocytes (without elaborating pro-inflammatory mediators); activate 
macrophage phagocytosis of microorganisms and apoptotic cells; increase the exit of 
phagocytes from the inflamed site through the lymphatics, and stimulate the expression of 
molecules involved in antimicrobial defence (49, 50). The last, but equally important aspect of 
inflammation resolution is that parenchymal cells, which hosted the inflammatory event are 
reverted into a non-inflammatory phenotype and destroyed parenchymal cells are replaced 
(51).  
 
1.4.  Alveolar epithelial repair 
The diffuse alveolar damage accompanying the acute phase of lung injury is ultimately 
followed by effective endo-epithelial barrier renewal to restore normal lung function. The 
most damaged structure is the alveolar type I cell, which appears to be more sensitive to injury 
then alveolar type II cells (11). Of note, endothelial cell damage is subtle and seems to be of 
minor importance in maintenance of alveolar barrier integrity. The key features of successful 
alveolar repair after ALI are oedema fluid clearance and reconstitution of a normal alveolar 
structure. Epithelial repair consists of proliferation and differentiation, adhesion, spreading 
and migration of alveolar epithelial cells. As described in Section 1.1.1. AEC II are a source 
of distal airway epithelial recovery. The daily turnover rate of AEC II is remarkably low at 
4% but rapidly increases after injury (11). However, epithelial cell proliferation needs several 
hours to take place and 1-2 days to become significant (Fig. 2) (8).  
Adhesion to the extracellular matrix, spreading and migration have been suggested to precede 
the epithelial proliferative phase. Hence, AEC II have been shown to migrate in vitro in 
response to different growth factors and cytokines, such as epidermal growth factor (EGF), 
transforming growth factor-alpha (TGF-α), laminin, fibronectin, and IL-1ß and TNF-α to a 
lesser extent. Interestingly AEC II do not need to be in a proliferative phase to exhibit 
increased motility (52). However, the in vivo contribution of AEC spreading and migration in 
epithelial repair has been poorly investigated due to the lack of sensitive tools to study these 
processes in vivo. Of note, while migration can take up to a few minutes for neutrophils, it 
needs several hours to be initiated in AEC (52).  
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Both migration and proliferation of AEC require modulators. Heparin sulphate-binding 
cytokines – such as epidermal growth factor (EGF), hepatocyte growth factor (HGF), 
transforming growth factor alpha (TGF-α), keratinocyte growth factor (KGF), and fibroblast 
growth factor (FGF) were identified as promoters of epithelial cell migration and proliferation 
after lung injury (53-55). 
Transforming growth factor beta (TGF-ß) participates in alveolar repair by attenuating the 
inflammatory cytokine production from AMφ (56), enhancing production of matrix protein 
components (57) and regulating integrin expression on epithelial cells (58). Similarly, platelet 
derived growth factor (PDGF) is mitogenic for fetal alveolar epithelial cells (59), and it has 
been demonstrated to enhance DNA synthesis in adult rat alveolar epithelial cells (60).  
Besides the soluble modulators, alveolar epithelial repair is tightly regulated by the cells 
neighbouring AEC in the alveolus, particularly resident alveolar macrophages. However, the 
molecular mechanisms underlying the crosstalk between AEC and the other resident alveolar 
cells during alveolar repair remain largely elusive. 
 
Figure 2. Epithelial cell repair following acute lung injury. The different stages involved in the 
process are illustrated. ALI = acute lung injury; LAEC = lung alveolar epithelial cell.  
Adapted from Berthiaume et al. 1999 (8). 
 
1.4.1.  Macrophage-epithelial crosstalk during alveolar epithelial repair 
Resident alveolar macrophages are suggested to play a dual role in ALI. During the acute 
inflammatory phase AMφ acquire a pro-inflammatory phenotype engaged to dispose of the 
pathogens from the alveolar space, followed by the switch into an anti-inflammatory 
phenotype which initiates the resolution phase, as described in Section 1.3. The later AMφ 
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phenotype has been associated with the release of epithelial growth factors and anti-
inflammatory cytokines, and hence with the potential to enhance alveolar repair.  
In this respect Morimoto et al. showed that AMφ ingesting apoptotic neutrophils in vitro 
produce significant amounts of the potent epithelial mitogen HGF (61). Similarly, Fadok et al. 
provided evidence that upon phagocytosis of apoptotic cells AMφ produce TGF-ß, PGE2 and 
platelet- activating factor (PAF) – anti-inflammatory cytokines which consequently dampen 
LPS-induced production of pro-inflammatory cytokines by AMφ (56, 62). These studies 
emphasize the potential of AMφ to acquire an anti-inflammatory, reparative phenotype during 
later stages of inflammation, i.e. upon contact with apoptotic neutrophils or host cells (Fig. 3).  
 
Figure 3. Regulation of macrophage activation by interaction with apoptotic cells. Activated 
macrophages (Mφ) can accelerate leukocyte apoptosis and trigger resident cell apoptosis. Subsequent 
phagocytosis of the apoptotic progeny deactivates or ‘reprograms’ the macrophage, which then 
receives signals to promote repair and/or emigrate. Adapted from Serhan 2005, (63). 
 
Interestingly, several reports evidenced that AMφ may promote epithelial repair irrespectively 
of the contact with apoptotic cells. In this line, supernatants from silica-exposed AMφ 
increased DNA synthesis in AEC II in vitro via macrophage soluble mediators such as PDGF-
like and IGF-like molecules (60). Furthermore, the macrophage pro-inflammatory cytokine 
IL-1ß enhanced in vitro epithelial repair by stimulating AEC spreading and migration via 
induction of TGF-α and EGF production in epithelial cells (64). TNF-α on the other hand 
stimulated in vitro proliferation of gastric epithelial cells by inducing arachidonic 
acid/prostaglandin pathway (65), whereas in vivo it has been demonstrated to enhance fluid 
clearance following bacterial pneumonia (66). Hence, the latter studies brought forward the 
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notion that not only anti-inflammatory, but also the “early” pro-inflammatory AMφ may 
contribute to epithelial repair; however the mechanisms need to be further investigated. 
1.4.2.  Granulocyte-macrophage colony-stimulating factor (GM-CSF) 
Granulocyte macrophage colony-stimulating factor (GM-CSF) is produced by lung cells 
predominantly by alveolar macrophages and AEC II (67). It has been mainly recognized as a 
growth factor for the cells of the phagocytic lineage but also stimulates differentiation of 
eosinophils, erythrocytes, megakaryocytes and dendritic cells (68). Separately from its role in 
progenitor cell proliferation and differentiation, GM-CSF stimulates a number of functions of 
AMφ, such as cytokine expression, killing of pathogens, surface receptor-antigen expression, 
adherence and oxidative metabolism (67).  
The effects of GM-CSF are mediated through heteromeric cell-surface receptors. The GM-
CSF receptor (GM-CSF R) is composed of low-affinity α (GM-CSF Rα) and high-affinity ß 
(GM-CSF Rß) chains (69, 70). Neither GM-CSF Rα nor GM-CSF Rß contains a tyrosine 
kinase catalytic domain but the ß chain constitutively associates with Janus kinase-2 (JAK-2), 
which is a tyrosine kinase (71). GM-CSF binds with the α-subunit, which then associates with 
the ß subunit and initiates JAK-2 phosphorylation and downstream signalling, such as 
activation of STAT or MAPK pathways (72).  
Surprisingly, mice genetically deficient of GM-CSF (GM-/- mice) revealed a specific lung 
phenotype resembling to the human disease pulmonary alveolar proteinosis (PAP), which was 
found to be associated with AMφ metabolic dysfunction. Therefore, GM-CSF has been 
assigned a crucial role in the surfactant homeostasis in healthy lungs (73, 74). 
Furthermore, studies in transgenic mice created in the GM-/- background specifically 
overexpressing GM-CSF in AEC II (SPC-GM), revealed prominent hyperplasia and 
proliferation of AEC II (75), indicating these cells to be a GM-CSF target. Similarly, Joshi et 
al. demonstrated the expression of GM-CSF receptors on AEC II (76). Furthermore, GM-CSF 
exhibited epithelial protective effects after hyperoxic lung injury alone or associated with 
Pneumocystis murina pneumonia, such as preservation of the epithelial barrier, due to reduced 
alveolar wall cell apoptosis (77, 78). The aforementioned studies strengthened the notion that 
GM-CSF additionally targets other cells than phagocytes, such as AEC II, and hence may be 
involved in alveolar epithelial repair following ALI. 
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1.5.  Klebsiella pneumoniae 
Klebsiella pneumoniae is a gram-negative, encapsulated, facultative anaerobic bacterium; 
clinically the most important member of the Klebsiella genus of Enterobacteriaceae. It is 
ubiquitous and hence naturally occurs in the soil, and in the normal flora of the mouth, skin, 
and intestines in humans (79). K. pneumoniae causes severe pneumonia and frequently affects 
immunocompromized patients and alcoholics. Klebsiellae are also important in nosocomial 
infections among adult and paediatric populations, and account for approximately 8% of all 
hospital-acquired infections. In this line, outbreaks of Klebsiellae infections in neonatal units 
have been widely reported and are frequently associated with systemic infections, and death 
(80). This becomes increasingly important since an increasing number of nosocomial K. 
pneumoniae isolates are resistant to multiple antibiotics treatment. The infection is 
characterised by destructive changes, necrosis, inflammation, and haemorrhage within the 
lung tissue (81).  
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2. Aims of the study 
In the presented thesis the following questions have been addressed: 
1) Can early activated, pro-inflammatory resident alveolar macrophages initiate alveolar 
epithelial repair processes following lung inflammation? 
2) What are the underlying molecular signals mediating macrophage-epithelial crosstalk 
during these processes, in vitro and in vivo?  
To answer these questions an in vitro model of crosstalk between murine alveolar epithelial 
cells and lipopolysaccharide (LPS)–stimulated resident alveolar macrophages was established. 
Furthermore, LPS and K. pneumoniae-induced acute lung injury models were used to evaluate 
in vivo macrophage-epithelial crosstalk mechanisms involved in alveolar epithelial repair. 
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3. Material and Methods 
3.1.  Animals 
Wild-type C57BL/6 mice (weight 18-21g) were purchased from Charles River (Sulzfeld, 
Germany). GM-CSF-deficient mice (GM-/-) were produced by gene-targeting on a C57BL/6 
background, as previously described (74). Transgenic mice overexpressing GM-CSF in AEC 
II were generated in GM-/- mice by expression of a chimeric gene containing GM-CSF under 
control of the human SP-C promoter, i.e. in AEC II (SPC-GM) (82). Both GM-/- and SPC-GM 
mice were a kind gift from Dr. Jeffrey Whitsett (University of Cincinnati, Ohio). Animals 
were kept under special pathogen-free conditions and used at 8-11 weeks of age. All animal 
experiments were approved by the local government committee of Giessen.  
 
3.2.  Isolation and culture of murine primary alveolar epithelial cells and 
preparation of lung homogenates 
Type II AEC were isolated by the method developed by Corti et al. (83), with some 
modifications (43, 84). Briefly, lavaged and perfused lungs were filled with 1.5 ml sterile 
Dispase and 0.5 ml low-melting-point agarose (1%), removed and placed in Dispase for 40 
min at room temperature. The lung parenchyma was subsequently teased from the airways 
and minced in DMEM/2.5% HEPES with 0.01% DNase, and successively passed through 
100, 40, and 20 µm nylon filters. At this stage the lung homogenates were obtained in a form 
of single-cell suspension. The cell suspension was collected by centrifugation and incubated 
with biotinylated CD45, CD16/32 and CD31 to deplete leukocytes and endothelial cells, for 
30 min. After washing, the contaminating cells were removed by incubation with streptavidin-
linked magnetic particles, and subsequent magnetic separation. The supernatant was 
recovered and the purity of the AEC preparation was routinely assessed by flow cytometry. 
Final cell suspension always consisted of > 95% of AEC, i.e. pro-SP-C+ cells. Viability was 
always >95%, as assessed by trypan blue dye exclusion. AECs stained positive for wide-
spread cytokeratin (WSCK) throughout day 5 of culture as analysed by flow cytometry. For 
real-time PCR, Western Blot analysis, cytokine quantification and cell-counting the AEC 
were seeded in a 24-well cell-culture plate at a density of 2.5-5.0 x105 /well and cultured for 
up to 5 days. For [3H]-thymidine-incorporation experiments 1.2 x105 AEC were seeded in a 
48-well plate. For flow cytometry analysis AEC were grown on the lower side of the transwell 
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filter inserts (6.4 mm diameter, 8 µm pore size) at a density of 3x105 and grown for up to 5 
days.  
For matrigel:collagen experiments freshly isolated AEC were seeded in a 24-well plate 
previously coated for 30 min with a 1:1 mixture of matrigel:collagen at a density of 4x105 
cells/well. For mono-culture experiments AEC were left to attach for 5 h in medium 
containing 10% FCS, subsequently starved in medium with 0.1% FCS and cultured for up to 3 
days. For proliferation analysis, after the initial 5 h attachment, AEC were stimulated with 
GM-CSF as indicated. The cells were removed from the matrigel:collagen matrix by 30 min 
incubation with 0.1% Collagenase A in Dispase solution at 37°C, and used for further 
applications. 
AEC medium was composed of Dulbecco’s MEM containing 4.5 g/l glucose, 12.5 mM 
HEPES, 2mM L-glutamine and penicillin/streptomycin. 
Epithelial cells were kept in medium supplemented with 10% FCS for the first 16 to 24 h, and 
thereafter cultured in medium with 0.1% FCS (starving medium). 
 
3.3.  Isolation and culture of murine primary resident alveolar 
macrophages 
Murine resident alveolar macrophages were isolated by bronchoalveolar lavage (BAL) from 
mouse lungs with sterile, ice-cold 2 mM PBS/EDTA. After centrifugation (1400 rpm, 10min), 
AMφ were recovered in RPMI 1640 containing 10% FCS, 2mM L-glutamine and antibiotics. 
Before AEC/AMφ co-culture experiments AMφ seeded at a density of 2-2.5 x 105 /well in a 
24 well plate or on transwells were left to adhere for 1-2 h. 
 
3.4.  AEC/AMφ in vitro co-culture  
For AEC/AMφ co-culture experiments, AEC were seeded on the lower side of transwells at a 
density of 3.0–5.0 x105/well. For real-time PCR analysis and cytokine quantification AEC 
were grown on transwells for 60 h (70% confluence) in medium containing 10% FCS and 
then placed above the AMφ grown in a 24 well plate (Fig. 4). Co-culture was maintained for 
the next 48 h, in 500 µl of AEC medium supplemented with 0.1% FCS. For [3H]-thymidine-
incorporation AEC were grown on transwells for 16 h in 10% FCS medium, starved for 10 h 
in 0.1% FCS medium and co-culture started immediately thereafter for 48 h. For 
matrigel:collagen co-culture experiments freshly isolated AEC were left to attach for 5 h in 
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medium containing 10% FCS, washed and immediately thereafter the co-culture with AMφ 
(grown on transwells) was started and maintained in starving medium (0.1% FCS) for 48-72 
h. 
In selected experiments, neutralizing anti-TNF-α or appropriate isotype IgG antibodies 
(1 µg/ml) were added to the medium of each AEC/AMφ co-culture-well at 0, 6, 12 and 20 h 
after LPS stimulation. 
 
Figure 4. A scheme of the in vitro co-culture model of primary murine AEC and AMφ. AEC were 
grown on the lower side of the transwells and then co-cultured with primary AMφ for 48 h, with or 
without LPS. 
 
3.5.  Gene expression analysis 
3.5.1.  Isolation of total RNA 
AEC and AMφ were lysed with TRK buffer and total cellular RNA was isolated with spin 
columns using PeqGold Total RNA kit. Subsequently, RNA was quantified by a 
spectrophotometer (Nanodrop ND-100). Total RNA from transwell co-cultured AEC was 
obtained by pooling the quantity from 3-5 transwells.  
3.5.2.  cDNA synthesis  
After isolation mRNA was transcribed into cDNA by reverse transcriptase (RT) -reaction. To 
perform cDNA synthesis 50-500 ng of total RNA was mixed with water, heated for 5 min at 
70° C, immediately thereafter transferred on ice and RT mix was added. 
The total reaction volume was 25 µl. The mixture was then incubated for 1 h on 37° C, heated 
on 94° C for 7 min to inactivate the enzyme. The obtained cDNA was either used for real-time 
PCR or stored in -20° C until further use.  
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3.5.3.  Real-time quantitative PCR (qPCR) 
Quantitative gene expression analysis was performed by real-time PCR, using Platinum 
SYBRGreen qPCR SuperMix-UDG. DNA was detected and quantified with the fluorescent 
dye SYBR Green I which offers a linear dose response over a wide range of target 
concentrations, and binds directly to double-stranded (ds) DNA. As dsDNA accumulates the 
dye generates a signal that is proportional to the DNA concentration. ROX reference dye was 
used to normalize the fluorescent signal between reactions. PCR reactions were performed in 
25 µl volume by using the qPCR mix. 
 
Cycling conditions were as follows: 95° C for 5 min, 45 cycles of 95° C for 10 s, 60° C for 
30 s and 72° C for 10 s. Formation of a single specific PCR product was confirmed by melting 
curve analysis and agarose gel electrophoresis. Mouse hydroxymethylbilane synthase 
RT mix Stock solution  Quantities per reaction 
5x First strand buffer 250 mM Tris-HCl (pH 8.3), 375 
mM KCl, 15 mM MgCl2  
5 µl 
Random hexamers 100 ng/µl 150 ng 
dNTPs 10 mM each 2.5 nmol each 
DTT 100 mM 250 nmol 
Ribonuclease inhibitor 40 U/µl 20 U 
MMLV 200 U/µl 150 U 
qPCR mix Stock solution Quantities per reaction 
SYBRGreen mix 2x (Taq DNA Polymerase, SYBR Green dye 
I, Tris-HCl, KCl, 6 mM MgCl2, 400 µM 
dGTP, dATP, dCTP, 800 µM dUTP, uracil 
DNA glycosylase, stabilizers) 
13 µl 
MgCl2 50 mM 50 nmol 
Forward primer 10 pmol/µl  5 pmol 
Reverse primer 10 pmol/µl 5 pmol 
H2O Molecular biology grade 5 µl 
cDNA 2,5 ng/µl 12,5 ng 
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(HMBS) served as a reference gene for all real-time PCR reactions. Relative changes in gene 
expression were determined with the ∆Ct method using the following formula: ∆Ct = Ctreference 
– Cttarget. The oligonucleotide primer pairs used in qPCR were designed by Primer Express 2.0 
and GenScript (https://www.genscript.com/ssl-bin/app/primer) programs. All primer 
sequences are listed in Supplement 9.3. 
 
3.6.  Protein expression analysis 
3.6.1.  Immunofluorescence  
3.6.1.1. Immunofluorescence staining of cultured AEC 
For immunofluorescence staining, AEC were either cultured on chamber-slides or on 
transwells. Prior to staining AEC were permeabilized and fixed in an ice-cold (-20°C) mixture 
of acetone and methanol (1:1) for 5 min, washed in 0.1% BSA/PBS and blocked with 3% 
BSA/PBS solution to prevent unspecific binding, until further antibody-staining. For primary 
antibody staining AEC were incubated overnight (anti-pro-SP-C and anti-T1-α antibodies, 
diluted 1:400 and 1:250, respectively) at 4°C, subsequently washed three times in 0.1% 
BSA/PBS (5 min each wash), and immediately thereafter incubated with Alexa 555-labelled 
anti rabbit IgG and Alexa 488-labelled anti hamster IgG secondary antibodies, (diluted in 
0.1% BSA/PBS, 1:1000), for 1 h at RT. Secondary antibody excess was removed by three 
subsequent washes (in 0.1 % BSA/PBS, 5 min each). The slides were then mounted with 
Vectashield mounting medium (containing DAPI for nuclear staining). Cells were imaged 
with conventional fluorescence microscopy using a Leica DM 2000 fluorescence microscope 
at the indicated magnification and Leica digital imaging software. 
3.6.1.2. Immunofluorescence staining of lung tissue slices 
Mouse lungs were perfused and lavaged with 500 µl 2mM EDTA/PBS aliquots to remove 
alveolar leukocytes, subsequently inflated with 1.5 ml of 1:1 mixture of TissueTek (Sakura) 
and PBS, removed en bloc and snap-frozen in liquid nitrogen. Lung tissue cryosections (7µm) 
were mounted on glass slides and left to dry overnight at room temperature. Immediately 
thereafter the slides were incubated overnight with primary antibodies (pro-SP-C and Ki-67, 
diluted 1:400 and 1:25, respectively) or respective isotype IgG. Incubation with secondary 
antibodies (Alexa 555 anti-rabbit IgG and Alexa 488 anti-rat IgG) diluted in BSA 0.1%/PBS 
(1:1000) was performed for 1 h at room temperature, the slides were then washed, mounted 
with a DAPI-containing mounting medium and left to dry overnight. Slides were analysed 
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with a Leica DM 2000 fluorescent microscope at the indicated magnification using Leica 
digital imaging software. 
3.6.2.  Flow cytometry 
For flow cytometric antigen detection AEC grown on transwells were trypsinized 
(Trypsin/EDTA 1x, 1-2 min), pooled (3-5 transwells) and washed once in PBS. Subsequently 
AEC (cultured or freshly isolated) or lung homogenate samples were fixed for 15 min in 1% 
paraformaldehyde (PFA)/PBS solution (4° C), washed once in FACS buffer (PBS-/- 
supplemented with 7.4% (v/v) EDTA and 0.5% (v/v) FCS), and then incubated for 15 min in 
Saponin buffer (0.2% Saponin in FACS buffer) for permeabilization and hence detection of 
both, extracellular (CD45 and T1-α) and intracellular antigens (pro-SP-C, Ki-67). Unspecific 
antibody binding was inhibited by adding 10 µl Fc-Block. Subsequently, the cells were 
incubated with primary antibodies pro-SP-C (diluted 1:000), PE-conjugated Ki-67 
(undiluted), biotinylated CD-45 (1:100) and T1-α (1:250), or with respective isotype IgG 
antibodies. The cells were then stained with the secondary antibodies (Alexa 488 or Alexa 647 
anti-rabbit IgG and Alexa 647 or Alexa 488 anti-hamster IgG, all diluted 1:500 in Saponin 
buffer) for 20 min at 4°C. Immediately thereafter, where applicable, the cells were incubated 
with 5 µl streptavidin-conjugated APC-Cy7 antibody (1:100 diluted), for 3 min. Primary and 
secondary antibody excess was removed by two subsequent washes in Saponin buffer. Flow 
cytometry analysis was performed using a FACSCanto flow cytometer equipped with 
FACSDiva and WinMDI 2.8 software packages.  
3.6.3.  Western Blot 
AEC were washed once with cold PBS (4° C) and lysed in 50 µl lysis buffer (see below). The 
cell lysate was incubated on ice for 15 min and immediately thereafter centrifuged at 13 000 
rpm for 15 min at 4° C. The supernatant was separated from the cell pellet and protein content 
was determined by using a commercial spectrophotometric assay, Bio-Rad DC (detergent 
compatible). The assay is similar to the well-documented Lowry assay (85). Proteins (5-
10 µg) were separated according to the size by SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) under reducing and denaturing conditions in 1 x SDS-running buffer (80 V, 40 mA, 2 
h). Gels were composed of 5% stacking and 10% running gel. Prior to loading, proteins were 
mixed with loading buffer and boiled for 5 min on 95° C. 
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Lysis buffer  
Tris (pH 7.5) 20 mM 
NaCl 150 mM 
Na2EDTA 1 mM 
EGTA 1 mM 
NP-40 0.5 % 
Na3VO4 2 mM 
Protease inhibitor mix 1x (Roche) 
 
1 x SDS running buffer  
Tris 25 mM 
Glycine 250 mM 
SDS 0.1% (v/v) 
 
Stacking gel (5%)  
Tris (pH 6.8) 125 mM 
Acrylamide 5 % 
SDS 0.1% (v/v) 
Temed 0.2% (v/v) 
APS 0.05% (w/v) 
 
Running gel (10%)  
Tris (pH 8.8) 375 mM 
Acrylamide 10 % 
SDS 0.1% (v/v) 
Temed 0.1% (v/v) 
APS 0.03% (w/v) 
 
Separated proteins from the gels were then transferred onto hybond-P PVDF-membrane using 
the Bio-Rad transfer chamber and transfer buffer, at 120 V and 265 mA, for 1 h. Membranes 
were then blocked for 30 min with a blocking buffer, and subsequently incubated overnight at 
4°C with anti-STAT5 or anti-phospho STAT5 antibodies (both diluted 1:1000 in blocking 
buffer). After washing with washing buffer they were then incubated with 1:1000 diluted anti-
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rabbit horseradish peroxidase–conjugated secondary antibody. Final detection of protein was 
performed using the enhanced chemiluminescent Western blotting system and recorded on an 
autoradiograph. To remove bound antibodies and to reprobe the membranes, they were 
incubated at room temperature for 1 h in stripping buffer containing PBS/0.1 M 
glycine/0.375% HCl. 
 
Transfer buffer (pH 7.4)  
Tris  25 mM 
Glycine 192 mM 
Methanol 20% (v/v) 
 
Washing buffer  
PBS  1 x 
dH2O  
Tween 20 0.1 % (v/v) 
 
Blocking buffer  
Non-fat dry milk 5% (w/v) 
PBS 1 x 
Tween 20 0.1 % (v/v) 
 
Stripping buffer  
Glycine  0.1 M 
dH2O  
HCl 0.375% 
 
3.6.4.  Cytokine quantification 
Cytokine levels in cell culture supernatants and bronchoalveolar lavage fluid were measured 
using commercially available sandwich ELISA kits. Standards, control, and samples were 
pipetted into the wells, incubated for 2 h at RT, followed by five washing steps with an 
ELISA autowasher. After 2 h of incubation with the conjugate solution and repetitive 
washing, substrate solution was added to each well for 30 min, and then the reaction was 
stopped. Optical density was measured using a microplate reader set to 450 nm; the sample 
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values were read off the standard curve. Detection limits were 7.8 pg/ml for GM-CSF, 5.1 
pg/ml for TNF-α, 2 pg/ml for CCL2 and 1.5 pg/ml for MIP-2. 
 
3.7.  In vitro proliferation assays 
3.7.1.  [3H]-thymidine incorporation 
Freshly isolated AEC II were maintained 16 h in medium supplemented with 10% FCS 
followed by 8-10 h of starvation (medium with 0.1% FCS) to achieve growth arrest before 
stimulation (recombinant TNF-α or GM-CSF) or begin of co-culture with AMφ, for 48 h. 
[3H]-thymidine (0.25 µCi/well) was added in the culture wells for the final 5 h of the 
incubation. Afterwards, supernatants were aspirated and the cells were washed three times 
with PBS before lysis with 0.5 M NaOH. Before measurement cell-culture plates with lysis 
solution were shaken for 30 min at RT. The cellular [3H]-thymidine content of each well or 
transwell was quantified by scintillation counting. In every experiment each condition was 
performed in quadruplicates. Results are expressed as fold induction of untreated cells (i.e. 
AEC in starving medium (0.1% FCS)). 
3.7.2.  Cell counting 
For cell counting AEC were treated in the same way as for [3H]-thymidine incorporation 
(Section 3.7.1.). After 48 and 72 h of stimulation, in mono/co-culture and matrigel:collagen 
mono/co-culture respectively, the cells were counted in a haemocytometer and by flow 
cytometry. Briefly, following trypsinization or matrigel:collagen release AEC were washed 
once in PBS and subsequently the cell pellet was resuspended in 120 µl of FACS buffer – 10 
µl cell suspension were used for hemacytometer counting and 110 µl for flow-cytometry (60 
sec, medium speed for each sample). The results are presented as fold induction of untreated 
AEC (in 0.1 % FCS).  
 
3.8.  In vivo mouse treatment protocols 
Mice were sedated with xylazine hydrochloride (2.5 mg/kg, im) and ketamine hydrochloride 
(50 mg/kg, im), followed by fur/skin desinfection and subsequent shaving of the area above 
the trachea. A small incision was made and surrounding tissue bluntly dissected to expose the 
trachea. An Abbocath catheter was inserted in the trachea and subsequently LPS (10 
µg/mouse) dissolved in sterile PBS in a total volume of 70 µl was slowly instilled, under 
stereomicroscopic control. Subsequently the skin was sutured; mice were left to recover from 
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anaesthesia and then returned to their cages, with free access to food and water (3, 86). Wild 
type (wt), GM-/- and SPC-GM mice were intratracheally challenged with LPS for different 
time intervals (6, 12, 24, 48, 96, 148 and 240 h). In selected experiments LPS was applied 
together with function blocking anti-TNF-α antibodies or respective isotype IgG control 
antibodies (10 µg/mouse) for 6 or 96 h, in a total volume of 70 µl. 
 
3.9.  Collection and analysis of blood samples and bronchoalveolar lavage 
fluid (BALF) 
Mice were sacrificed with an overdose of Isoflurane at the indicated time intervals, and the 
abdominal cavity was opened to expose the inferior vena cava. Blood was drawn with a 23-
gauge cannula connected to a 1 ml syringe, and immediately thereafter transferred into a 1.5 
ml collection tube.  
The bronchoalveolar lavage fluid was collected as follows: the trachea was exposed and 
cannulated by a shortened 21-gauge cannula connected to a 1 ml syringe, followed by 
consecutive instillation and collection of 300, 400 and 500 µl of ice-cold 2 mM EDTA/PBS 
(concentrated BAL fluid). The cells from concentrated BALF were separated by 
centrifugation (1400 rpm, 10 min, 4° C), whereas the supernatant was harvested into a 
collection tube and was further used for cytokine quantification or alveolar leakage 
determination (see Sections 3.6.4 and 3.10). Subsequently, BAL was completed with 
additional instillation-collection cycles of 500 µl EDTA/PBS, until the final volume of 4 ml 
was recovered (diluted BAL fluid). After centrifugation (1400 rpm, 10 min, 4° C) the cells 
from diluted BALF samples were resuspended in 1 ml RPMI (supplemented with L-
glutamine, 10% FCS and antibiotics) and pooled together with the cells from concentrated 
BAL. The supernatants from diluted BAL were discarded. The cell number in the pooled 
samples was counted in a haemocytometer, and was defined as total BALF leukocytes. BALF 
leukocyte subpopulations were determined by Pappenheim-stained cytocentrifuge 
preparations, as described in Section 3.9.1. For further flow cytometric analysis of BALF 
cells, the pooled samples were fixed in 1% PFA/PBS solution (15 min, on ice) and 
subsequently handled as described in Section 3.6.2.   
3.9.1.  Pappenheim-stained cytocentrifuge preparations 
For identification and quantification of leukocyte subpopulations in pooled BAL samples 
Pappenheim staining of cytocentrifuge preparations were used (87). Briefly, cytospins were 
prepared from every pooled BALF sample, containing 30000-50000 cells in 100 µl, and 
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subsequently stained for 5 min in May-Grünwald stain and 10 min in 5% of Giemsa Azur-
Eosin-Methylenblue solution. Total resident alveolar macrophages and neutrophil numbers in 
BALF were determined by differential cell counts using overall morphological criteria, 
including differences in cells size and shape of nuclei, and subsequent multiplication of 
obtained percentage values with the respective total BALF leukocyte counts.  
 
3.10. In vivo lung permeability assay 
For the determination of alveolar leakage mice received an intravenous injection (into the tail 
vein) of 1 mg FITC-labelled albumin in 100 µl of sterile NaCl 0.9%. 45 min later, BALF and 
blood samples were collected as described in Section 3.9. Blood samples were incubated for 3 
h at RT until coagulation occurred and serum was recovered after centrifugation (4000 rpm, 
15 min, RT). FITC fluorescence was measured in duplicates in concentrated BAL fluid and 
serum samples (diluted 1:100 in PBS) and compared to standard samples serially diluted 1:10 
with PBS, using a fluorescence spectrophotometer operating at 488 nm absorbance and 525 ± 
20 nm emission wavelengths, respectively. The lung permeability index is defined as the ratio 
of fluorescence signals of concentrated BALF samples to fluorescence signals of 1:100 
diluted serum samples and given as arbitrary units (AU). 
 
3.11. Measurement of in vivo proliferation of AEC II  
The proportion of proliferating AEC II in lung homogenates was investigated by flow 
cytometric staining with antibodies detecting the proliferation marker Ki-67. Lung 
homogenate samples were prepared as described in Section 3.2., the cells were fixed and 
permeabilized (Section 3.6.2.) and subsequently co-stained with Ki-67 PE-conjugated 
antibody, pro-SP-C and CD45 antibodies. Proliferating AEC II were determined as the Ki-67+ 
sub-population from CD45-/pro-SP-C+ cells, analysed against an isotype IgG control. 
3.11.1. Total AEC numbers in lung homogenates 
Total numbers of AEC II and AEC I in lung homogenates were determined by multiplying the 
percentage of pro-SP-C+ and T1-α+ cells, respectively (defined by flow cytometric staining) 
with the total lung homogenate cell counts (obtained with hemacytometer). Subsequently, 
total AEC numbers were calculated as a sum of total AEC II and AEC I numbers. 
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3.12. Infection experiments with K. pneumoniae 
The K. pneumoniae serotype 2 strain was purchased from ATCC (No 43816). K. pneumoniae 
was grown in Todd-Hewitt broth for 18-24 h. Determination of colony-forming units (CFU) 
was done by plating tenfold serial dilutions of bacterial suspensions on McConkey agar plates 
followed by incubation of the plates at 37°C for 18 hours and enumeration of the CFU. 
Bacteria were then diluted with PBS to the desired concentration (25 x 104 CFU/70 µl per 
mouse) and used for intratracheal infection. The procedure was in analogy to the intratracheal 
application of LPS (see section 3.8).  
. 
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4. Results 
4.1.  LPS-stimulation of AMφ induces AEC growth factors in co-culture 
Keratinocyte growth factor (KGF), vascular endothelial growth factor (VEGF), platelet –
derived growth factor (PDGF) and granulocyte macrophage colony-stimulating factor (GM-
CSF) have all been described as potent epithelial mitogens (60, 75, 88-91). To investigate 
whether AMφ are capable to induce expression of these growth factors in alveolar epithelial 
cells under inflammatory conditions, AEC were either mono- or co-cultured with AMφ for 
48 h, and treated with LPS (1 µg/ml for 48 h) or left untreated. Analysis of gene expression of 
the aforementioned growth factors in AEC revealed a significant upregulation of KGF, 
VEGF, PDGFa and, most prominent, of GM-CSF mRNA in AEC co-cultured with LPS-
stimulated AMφ compared to AEC in monoculture. Of note, LPS stimulation of mono-
cultured AEC or unstimulated ΑΕC/AMφ co-culture revealed no significant upregulation of 
any of the analysed growth factors in AEC (Fig. 5A). In contrast to the findings in AEC, AMφ 
did not show any significant regulation of the gene products named above, nor did co-culture 
with AEC influence their expression irrespective of the absence or presence of LPS (Fig. 5B).  
Additionally, expression of several other growth factors in AEC was analysed (Table 1), but 
only non-significant changes were observed upon LPS stimulation and co-culture with LPS-
stimulated AMφ. Hence, a slight upregulation of fibroblast growth factor 2 (FGF2) and 
platelet derived growth factor b (PDGFb) and downregulation of platelet derived growth 
factor d (PDGFd) were noted in AEC co-cultured with LPS-stimulated AMφ.  
Given that, among the growth factors analysed, GM-CSF mRNA upregulation was most 
pronounced, GM-CSF protein release in mono- and co-culture upon LPS stimulation was 
further investigated. As demonstrated in Fig. 6, AMφ  alone did not release significant 
amounts of GM-CSF into the supernatant, irrespectively of the presence or absence of LPS. 
AEC alone showed remarkably higher release of GM-CSF compared to AMφ, which was not 
significantly enhanced in presence of LPS. Supernatants from LPS-stimulated co-cultures, 
however, contained significantly higher amounts of GM-CSF than supernatants from AEC 
mono-cultures or from unstimulated co-cultures. Of note, presence of AMφ reduced GM-CSF 
levels observed in AEC mono-culture (Fig. 6, lanes 3-5), most likely due to macrophage GM-
CSF consumption. Collectively, these data indicate that AEC are the primary alveolar source 
of epithelial growth factors and that AMφ have the potential to significantly amplify epithelial 
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expression of various growth factors, in particular of epithelial GM-CSF, upon inflammatory 
stimulation. 
 
Figure 5. LPS-stimulated AMφ enhance the expression of growth factors in co-cultured AEC. 
Freshly isolated AEC cultured for 60 h on transwells were either mono-cultured and left unstimulated 
or were stimulated with LPS (1 µg/ml), or were co-cultured with unstimulated or LPS-stimulated 
resident AMφ for 48 h. Subsequently, relative gene expression of different growth factors was 
analysed in both cell types. (A) Relative mRNA expression of KGF, VEGF, PDGFa and GM-CSF, in 
unstimulated or LPS-treated mono-cultured AEC (lanes 1 and 2) or co-cultured AEC (lanes 3 and 4). 
(B) Relative mRNA expression of KGF, VEGF, PDGFa, and GM-CSF in unstimulated or LPS-treated 
mono-cultured AMφ (lanes 1 and 2) or co-cultured AMφ (lanes 3 and 4). Values are means ± SD from 
at least n=3 different experiments each of which was performed in triplicates; *p<0.05, ***p<0.001. 
ns, not significant. 
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Table 1. mRNA expression of growth factors in AEC mono or co-cultured, in the presence or absence of 
LPS. 
 
Figure 6. GM-CSF secretion in the supernatants from AEC/AMφ co-culture. GM-CSF release 
from mono-cultured AMφ (lanes 1 and 2), mono-cultured AEC (lanes 3 and 4) and AEC/AMφ co-
cultures (lanes 5 and 6) in the presence or absence of LPS was analysed by ELISA. All given values 
are means ± SD from n=5 different experiments each of which was performed in triplicates; *p<0.05, 
**p<0.01, ***p<0.001; ns, non-significant. 
 
4.2.  Epithelial GM-CSF expression is induced by alveolar macrophage 
TNF-α 
Given that LPS-stimulated AMφ induced GM-CSF expression in AEC, most likely by a 
soluble mediator, it was further assumed that the pro-inflammatory TNF-α might mediate 
these effects. AMφ secrete significant amounts of the pro-inflammatory cytokine TNF-α upon 
LPS treatment and in early phase of gram-negative infections (92, 93), and AEC are known to 
respond to TNF-α (43, 94). Accordingly, TNF-α solely originated from AMφ in the LPS-
treated AEC/AMφ co-cultures, whereas AEC did not release any detectable levels of TNF-α 
(Fig. 7, lanes 2 and 6).  
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Of note, both TNF-α receptors 1 and 2 (TNFR1/2) were expressed on cultured AEC on 
mRNA level (Fig. 8). 
 
Figure 7. Quantification of TNF-α levels in AEC/AMφ co-culture. TNF-α levels in supernatants 
taken from unstimulated and LPS-stimulated mono- and co-cultured AEC and AMφ were determined 
by ELISA. All given values are presented as means ± SD from n=3 independent experiments. 
***p<0.001. 
 
Figure 8. Expression of TNF-α receptors during AEC in vitro culture. Freshly isolated AEC were 
cultured for 5 days and mRNA expression of TNFR1 and TNFR2 was analysed at the indicated time-
points. All values are presented as means ± SD from n=3 independent experiments. TNFR1, TNF-α 
receptor 1; TNFR2, TNF-α receptor 2.  
 
To evaluate whether macrophage TNF-α induced GM-CSF production in AEC, neutralizing 
anti-TNF-α antibodies were applied in the co-culture model. Indeed, anti-TNF-α treatment 
significantly decreased epithelial GM-CSF expression in LPS-treated co-cultures, both on 
mRNA and protein level (Fig. 9). 
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Figure 9. Alveolar macrophage TNF-α mediates epithelial GM-CSF production. Anti-TNF-α or 
isotype IgG antibodies were added to the medium of LPS-stimulated AEC/AMφ co-cultures (1 µg/ml 
at 2, 12 and 20 h post LPS treatment), and after 48 h GM-CSF mRNA expression in AEC (A) and 
GM-CSF protein in AEC/AMφ co-culture supernatants (B) were determined. All values are means ± 
SD from n=3 independent experiments. *p<0.05, a-TNF-α, anti-TNF-α antibody; Iso IgG, isotype 
IgG. 
 
Moreover, stimulation of mono-cultured AEC with recombinant murine TNF-α resulted in 
increased expression of GM-CSF, both on mRNA and protein level in a time-dependent 
manner. The highest GM-CSF levels were observed at 48 h of TNF-α stimulation (Fig. 10). 
Taken together, these data demonstrate that macrophage TNF-α, released upon LPS 
recognition, induces GM-CSF expression in co-cultured AEC, indicating that resident lung 
macrophages induce the release of epithelial growth factors from AEC yet in the early phase 
of inflammation.  
 
Figure 10. Recombinant TNF-α induces GM-CSF production in AEC in vitro. AEC were 
stimulated with 100 ng/ml recombinant murine TNF-α for 6, 12, 24 and 48 h, and subsequently 
relative GM-CSF mRNA expression (A) and GM-CSF protein levels in culture supernatants (B) were 
measured. Values are means ± SD from n=3 independent experiments. *p<0.05, **p<0.01. Untr, 
untreated. 
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4.3.  GM-CSF receptor expression is associated with the AEC II phenotype 
To evaluate the GM-CSF signalling in epithelial cells, initially the expression of both GM-
CSF receptor subunits (α and ß) over the 5 days of in vitro culture was investigated. As shown 
in Fig. 11, freshly isolated AEC expressed both subunits of the GM-CSF receptor, but their 
expression decreased during 5 days of culture.  
 
Figure 11. Freshly isolated AEC express both GM-CSF receptor subunits. GM-CSF receptor (α 
and ß) relative expression was determined over 5 days of in vitro culture. Values are means ± SD from 
n=4 independent experiments. *p<0.05, **p<0.01. GM-CSFRα, GM-CSF receptor alpha subunit; 
GM-CSFRß, GM-CSF receptor beta subunit.  
 
Given that rat and human AEC II cultured on plastic cell-culture plates have been shown to 
change their phenotype during in vitro culture, acquiring features of AEC I (15, 95), it was 
further examined whether GMCSF receptor subunit expression might be related to the AEC II 
phenotype. Indeed, mRNA expression of the AEC II specific markers such as pro-SP-C (5), 
CCAAT enhancer binding protein alpha (C/EBPα) (96) and gamma amino-butyric acid pi-
subunit (GABRP) (97) was pronounced at day 0, and rapidly declined during 5 days of 
culture, whereas mRNA levels of the AEC I marker T1-α increased (98) (Fig. 12A).  
In addition, immunolabelling of these markers revealed corresponding results on protein level, 
as demonstrated by flow cytometry (representative dot plots, Fig. 12B and quantitative 
analyses of the respective proportions of pro-SP-C+ or T1-α+ AEC, Fig. 12C) and 
immunofluorescence (Fig. 12D). Of note, GM-CSF stimulation of AEC (Fig. 12A) did not 
influence AEC phenotype changes.  
Together, these data indicate that GM-CSF receptor subunits α and ß are expressed on freshly 
isolated AEC. Thus, epithelial expression of GM-CSF receptors is associated with the AEC 
type II phenotype, and decreased with in vitro trans-differentiation into AEC I-like cells.  
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Figure 12. Expression changes of the markers of type II and type I AEC phenotype during 5 
days of culture of untreated or GM-CSF-treated AEC. (A) Relative expression of AEC II (pro SP-
C, C/EBPα and GABRP) and AEC I (T1-α) markers. (B) Representative dot plots of pro-SP-C and 
T1-α expression of AEC at d 0, 1, 3, and 5 post isolation, untreated or GM-CSF stimulated, including 
staining with respective isotype controls. (C) Bar diagram representing the percentages of pro-SP-C+ 
(P1) and T1-α+ (P2) cells as gated in B. Values are presented as means ± SD from 3 independent 
experiments. (D) Representative immmunofluorescence staining of AEC at day 0, 1, 3 and 5 with pro-
SP-C (red) and T1-α (green), or respective isotype IgG; magnification x20. *p<0.05, ***p<0.001. Iso 
IgG, isotype IgG control. 
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4.4. GM-CSF signalling in AEC  
4.4.1.  GM-CSF stimulation is not associated with pro-inflammatory cytokine production 
in AEC 
Tanimoto et al. have recently demonstrated that GM-CSF stimulates pro-inflammatory 
cytokine production, such as monocyte chemoattractant protein-/CC-chemokine ligand 2 
(CCL2), via induction of the STAT5/JAK2 pathway (99). To investigate whether epithelial 
cells may respond in a similar manner to GM-CSF, AEC were stimulated at day 1 of culture 
with GM-CSF for various time intervals, and measured release of the major monocyte and 
neutrophil chemoattractants, CCL2 and MIP-2 (macrophage inflammatory protein 2) by 
ELISA. As demonstrated in Fig. 13, GM-CSF did not induce production of the chemokines 
CCL2 and MIP-2 in AEC, indicating that GM-CSF did not initiate a pro-inflammatory 
response in AEC. 
 
Figure 13. GM-CSF does not induce the release of pro-inflammatory chemokines in AEC. AEC 
at day 1 of culture were stimulated with 100 ng/ml GM-CSF for 6, 12, 24 and 48 h and subsequently 
CCL2 (A) and MIP-2 (B) production was determined in supernatants by ELISA. Untreated AEC were 
used as a control at each time point. Values are means ± SD from n=3 independent experiments. untr, 
untreated; ns, not significant. 
4.4.2.  AEC do not produce growth factors upon GM-CSF treatment 
Huffman Reed et al (75) suggested that the observed AEC II hyperplasia in the lungs of SPC-
GM may be indirectly mediated by GM-CSF-dependent induction of potent epithelial growth 
factors in epithelial cells. To evaluate this hypothesis AEC were stimulated at day 1 of culture 
with GM-CSF for 24 h and subsequently mRNA expression of several epithelial growth 
factors was analysed. However, non significant differences between untreated and GM-CSF 
stimulated AEC were observed, indicating that GM-CSF does not enhance expression of 
further epithelial growth factors in AEC (Table 2). 
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Table 2. Relative expression of growth factors in AEC after GM-CSF stimulation for 24 h at day 1 of AEC 
culture. 
 
4.4.3.  GM-CSF induces proliferative signalling in AEC  
GM-CSF receptor downstream signalling has been described to be mediated by various 
intracellular pathways involving STATs, MAPK and PI3K/Akt (100, 101). Stimulation of 
AEC at day 1 of culture with recombinant murine GM-CSF, induced rapid and transient 
phosphorylation of STAT5 (Fig. 14). STAT5 phosphorylation revealed to be associated with 
increased mRNA expression of the proliferation marker Cyclin D1 after 24 h of stimulation 
(Fig.15). 
 
Figure 14. GM-CSF induces STAT5 phosphorylation in AEC. Representative western blot analysis 
of STAT5 phosphorylation in AEC stimulated with GM-CSF (500 pg/ml) at day 1 of culture for the 
indicated time points, total STAT5 was used as a loading control.  
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Figure 15. Cyclin D1 mRNA expression is upregulated upon GM-CSF stimulation of AEC. AEC 
at day 1 of culture were stimulated with GM-CSF (100 ng/ml) for 24 h, and subsequently Cyclin D1 
mRNA expression was analysed. Untreated AEC were used as a control. Values are means ± SD from 
n=3 independent experiments. *p<0.05; untr, untreated. 
 
Moreover, GM-CSF stimulation of AEC at day 1, but not at day 3 of culture, resulted in 
increased proliferation, as assessed by [3H]-thymidine incorporation and cell-counting (Fig. 
16). Collectively, these data indicate that a STAT5-dependent intracellular signal is induced 
upon GM-CSF receptor binding in day 1 AEC, resulting in Cyclin D1 expression and most 
likely mediating the subsequent proliferation.  
 
Figure 16. GM-CSF induces increased AEC proliferation. Freshly isolated AEC were left to adhere 
for 16 h, were then serum starved for 10 h and immediately thereafter stimulated with GM-CSF for 
48 h. Likewise, AEC at day 3 of culture were stimulated with GM-CSF for 48 h in serum starving 
medium. Subsequently, AEC proliferation was measured by [3H]-thymidine incorporation (A) and cell 
counting (B). Data is presented as fold induction of untreated control; values are means ± SD from n=4 
independent experiments performed in quadruplicate for [3H]-thymidine incorporation, and n=3 for 
cell-counting. *p<0.05, **p<0.01. Untr, untreated. 
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Of note, day 1 AEC, despite acquisition of the type I phenotype in terms of marker 
expression, were still capable to respond to the proliferative GM-CSF signal as opposed to 
day 3 AEC, indicating that day 1 AEC might functionally still possess type II characteristics 
during transition towards the type I phenotype. Likewise, AEC grown on matrigel:collagen 
matrix, thereby maintained in the “classical” type II phenotype until day 3 of culture (Fig. 17), 
similarly expressed and released GM-CSF upon LPS stimulation in the co-culture and 
responded to GM-CSF stimulation with enhanced proliferation (Fig. 18), further supporting 
the concept that the proliferative response to GM-CSF is related to the type II AEC 
phenotype. 
 
Figure 17. Matrigel:collagen culture delays in vitro differentiation of murine AEC. Freshly 
isolated AEC were seeded on matrigel:collagen pre-coated wells of 24-well plate and cultured for up 
to 3 days. (A) Relative mRNA expression of pro-SP-C and T1-α in AEC analysed at day 1, 2 and 3 of 
culture. (B) Flow cytometry quantification of pro-SP-C+ and T1-α+ cells; bar graphs show cells 
percentage of total epithelial cells. Values are presented as means ± SD from 3 independent 
experiments. ns, non-significant. 
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Figure 18. Matrigel:collagen cultured AEC express GM-CSF in co-culture with LPS stimulated 
AMφ and proliferate upon GM-CSF stimulation. Following isolation, AEC were left to attach for 
5 h on matrigel:collagen mixture, and immediately thereafter either co-cultured with unstimulated or 
LPS-stimulated AMφ or treated with GM-CSF. (A) After 48 h of co-culture AEC were released from 
the gel and GM-CSF relative mRNA expression (left diagram) and protein secretion into the co-culture 
supernatants (right diagram) were determined. Values are presented as means ± SD from 3 
independent experiments. (B) After 72 h of GM-CSF stimulation AEC proliferation was assessed by 
cell counting. Data is presented as fold induction of untreated control; values are means ± SD from 3 
independent experiments; *p<0.05; untr, untreated. 
 
4.5.  AEC proliferation is induced by macrophage TNF-α and mediated by 
GM-CSF 
Given that GM-CSF induced proliferative signalling in AEC at day 1 of culture and 
macrophage TNF-α stimulated GM-CSF expression in epithelial cells, the hypothesis that 
AEC proliferation might be induced by TNF-α in a GM-CSF dependent manner was tested. 
Therefore, AEC isolated from GM-CSF-deficient mice (GM-/- AEC) were stimulated at day 1 
of culture with recombinant TNF-α and compared with wild type AEC (wt AEC) for 
proliferation, assessed by [3H]-thymidine incorporation and cell counting. As given in 
Fig. 19A, GM-/- AEC did not show enhanced proliferation upon TNF-α stimulation, whereas 
TNF-α stimulated wt AEC demonstrated significantly increased proliferation, compared to 
untreated control (grey bars).  
Similarly, to evaluate whether LPS-stimulated AMφ may induce proliferation of epithelial 
cells via GM-CSF, GM-/- AEC grown on transwells were co-cultured with wt AMφ, with or 
without LPS and compared to co-cultured wt AEC for proliferation. Interestingly, wt AEC co-
cultured with AMφ in the presence of LPS showed remarkably increased [3H]-thymidine 
incorporation and AEC counts compared to unstimulated wt AEC in mono-culture, whereas 
LPS-stimulated AMφ did not influence the proliferation of GM-/- AEC (black bars). Likewise, 
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LPS-stimulated AMφ induced increased cell counts of the co-cultured wt AEC grown on 
matrigel:collagen matrix (i.e. “classical” AEC II), as shown on Fig. 19B. 
Collectively, this data clearly demonstrate that macrophage TNF-α released upon LPS 
stimulation, induces GM-CSF secretion in AEC which in turn induces AEC proliferation by 
an autocrine stimulation loop in vitro. 
 
Figure 19. GM-CSF mediates macrophage TNF-α induced AEC proliferation. (A) AEC mono-
cultures from wt and GM-/- mice were stimulated with recombinant TNF-α (100 ng/ml) for 48 h (grey 
bars) and proliferation was assayed by [3H]-thymidine incorporation (left panel) and cell counting 
(right panel). For proliferation analysis of co-cultured epithelial cells, wt AEC or GM-/- AEC were 
plated on transwells and co-cultured with LPS-stimulated resident AMφ for 48 h before proliferation 
analysis (black bars). Data is presented as fold induction of untreated cells (white bars). (B) Freshly 
isolated AEC were cultured on matrigel:collagen matrix, left to attach for 5 h and immediately 
thereafter co-cultured with LPS-stimulated AMφ. Cell counts were determined after 72 h of co-culture. 
Values are means ± SD from at least n=4 independent experiments performed in quadruplicates (for 
[3H]-thymidine incorporation) and n=3 for cell counting. *p<0.05, ***p<0.001; wt, wild type; untr, 
untreated.  
 
4.6.  TNF-α mediates AEC II proliferation following LPS-induced lung 
injury in vivo 
To evaluate the potential of macrophage TNF-α to mediate AEC II proliferation in LPS-
induced acute lung injury in vivo, AEC II proliferation at 96 h post LPS instillation was 
analysed in wt mice treated intratracheally with either anti-TNF-α or isotype control 
antibodies. Proliferating AEC II in lung homogenate samples were defined as CD45-/pro-SP-
C+/Ki67+, as demonstrated in the representative FACS plots in Fig. 20A. A remarkable 
increase in the percentage of proliferating AEC II was observed in LPS-injured mice after 4 
days post LPS installation compared to untreated mice. Interestingly, anti-TNF-α treatment 
significantly reduced the proliferating proportion of AEC II in LPS-challenged wt mice 
compared to treatment with isotype control antibodies (Fig. 20B). This finding was 
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additionally supported by immunofluorescence analysis of whole lung tissue slices co-stained 
for pro-SP-C and Ki-67, demonstrating that anti-TNF-α treatment markedly reduces the 
proportion of proliferating AEC II after LPS-challenge (pro-SP-C+/Ki-67+ cells, Fig. 20C). 
Significant changes in the total AEC II numbers during the treatment were not observed (Fig. 
20 D). 
Analysis of GM-CSF levels in the BAL fluid after 6 h of LPS-induced lung injury in mice 
revealed significantly lower GM-CSF release from alveolar cells when mice were treated with 
anti-TNF-α antibodies as compared to isotype-treated mice (Fig. 21).  
These data provide evidence that indeed macrophage TNF-α mediates alveolar epithelial cell 
proliferation in vivo following LPS-induced lung injury via induction of GM-CSF.  
 
Figure 20. TNF-α mediates AEC II proliferation in vivo. (A) Flow cytometric analysis of AEC II 
proliferation following LPS-induced lung injury. Lung homogenates from wt mice treated 
intratracheally with 10 µg LPS plus either anti-TNF-α, or isotype IgG antibodies, respectively, were 
analysed for CD45, pro-SP-C and Ki-67 expression. Representative dot plots show co-expression of 
pro-SP-C and Ki-67 (or respective iso IgG) of CD45-/pro-SP-C+cells (P1). (B) Quantification of FACS 
analysis of proliferating AEC II; bar graphs show the percentage of Ki-67+ of total AEC II (pro-SP-
C+/CD45-) in lung homogenates. Values are means ± SD from n=3 mice per group. (C) Representative 
immunofluorescent staining of pro-SP-C (red) and Ki-67 (green), or respective IgG, performed on 
lung cryosections from wt mice treated with either LPS + IgG or LPS + anti-TNFα antibodies for 96 h. 
Arrows depict proliferating AEC II; magnification x 20. D) Total AEC II numbers in lung 
homogenates of untreated, LPS + IgG and LPS + aTNF-α treated mice. The graph represents total 
AEC II numbers obtained from the respective AEC II percentages and total cell numbers of 
homogenates. Values are means ± SD from n=3 mice per group. **p<0.01, ***p<0.001. aTNF-α, anti-
TNF-α antibodies; IgG, isotype IgG antibodies; ns, non significant.  
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Figure 21. Neutralization of alveolar TNF-α reduces alveolar GM-CSF release after LPS 
challenge . Analysis of GM-CSF levels after 6 h of LPS in BALF from the various treatment groups 
was performed by ELISA. Values are means ± SD from n= 3 mice per group; *p<0.05. aTNF-α, anti-
TNF-α antibodies; IgG, isotype IgG antibodies; untr, untreated.  
 
4.7.  GM-CSF enhances AEC II proliferation and alveolar barrier renewal 
after LPS-induced acute lung injury 
To analyse the influence of GM-CSF on alveolar repair after LPS-induced lung injury in vivo, 
three groups of mice (wt, GM-/- and SPC-GM mice) were treated intratracheally with LPS for 
various time points and subjected to BAL for evaluation of amount and composition of 
alveolar leukocyte infiltration. As shown in Fig. 22, a pronounced accumulation of leukocytes 
was observed in the alveolar air spaces of all treatment groups between 12 and 48 h post LPS 
treatment.  
 
Figure 22. Quantification of total leukocyte numbers in BALF in wt (white bars), GM-/- (grey bars) 
and SPC-GM (black bars) mice in the time course post LPS instillation (n=3-5 mice per group, values 
are given as means ± SD).  
 
Morphologic analysis of leukocyte subpopulations from Pappenheim-stainied BALF cytospin 
preparations revealed that accumulating alveolar leukocytes were predominantly neutrophils 
Results  42 
 
(Fig. 23). Alveolar neutrophil peaks reached in wt, GM-/-and SPC-GM mice, were virtually 
identical.  
GM-/- mice had similar resident AMφ counts as wt mice in the early stages of LPS-induced 
inflammation, but substantially lower AMφ numbers during the later stages (48 h to 240 h). 
Total BALF AMφ  numbers were significantly higher in untreated SPC-GM mice as well as at 
all time intervals following LPS treatment compared to wt mice, an observation which has 
been described before (75, 77).  
 
Figure 23. Quantification of BALF leukocyte subpopulations from Pappenheim-stained 
cytocentrifuged preparations. Data is given as total cells and represents means ± SD from n=3 
animals per group; wt (white bars), GM-/- (grey bars) and SPC-GM (black bars). 
 
Analysis of BALF TNF-α levels upon intratracheal LPS administration in the three different 
treatment groups demonstrated that TNF-α was alveolarly released in wt, GM-/- and SPC-GM 
mice, most prominent at 6 h (Fig. 24). GM-CSF was released into the alveolar space of wt 
mice at 6 h post LPS treatment and was undetectable in GM-/- mice. SPC-GM mice produced 
significantly higher amounts of GM-CSF at baseline conditions (0 h) and at 6 and 12 h post 
LPS treatment compared to wt mice (Fig. 24). Of note, GM-CSF levels in constitutively 
overexpressing SPC-GM mice decreased between 12 and 24 h post LPS administration, most 
likely due to consumption by alveolar neutrophils and macrophages.  
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Figure 24. TNF-α and GM-CSF levels in BAL fluid from LPS-treated mice. Cytokine levels in 
BAL fluid of wt (white bars), GM-/- (grey bars) and SPC-GM (black bars) mice were quantified by 
ELISA; data is presented as means ± SD from n=3 mice per group; *p<0.05, **p<0.01, ***p<0.001. 
 
To investigate the role of GM-CSF in alveolar epithelial repair processes following LPS-
induced acute lung injury, AEC II proliferation in the various treatment groups was 
determined by flow cytometry and immunofluorescence on lung cryosections after 96 h post 
LPS instillation, a time point where recruited inflammatory leukocytes were virtually resolved 
from the air spaces and alveolar repair processes should likewise be initiated. As shown in 
Fig. 25A and B, proliferation of AEC type II was significantly higher in LPS-treated 
compared to untreated wt mice. Of note, the proliferating proportion of type II AEC was 
lower in GM-/- mice at 96 h post LPS administration, whereas in SPC-GM mice proliferation 
was comparable to wt mice. Likewise, the AEC II proportion in lung homogenates was 
significantly decreased in GM-/- mice and increased in SPC-GM mice compared to wt mice 
after 96 h post LPS instillation (Fig. 26A). In contrast, the percentage of AEC I (T1-α++ AEC) 
in lung homogenates was virtually identical before and after 96 h of LPS in all of the 
treatment groups (Fig. 26B). Similarly to AEC II proportions, the total AEC numbers (AEC II 
+ AEC I) in GM-/- mice significantly declined following LPS treatment (Fig. 26C), indicating 
that the observed decrease in the AEC II percentages at the indicated time point (Fig. 24 A) is 
most likely due to LPS-mediated AEC II injury. Collectively, these findings suggest that 
epithelial GM-CSF induces AEC type II proliferation and that the lack of epithelial GM-CSF 
is associated with impaired AEC II renewal in LPS-induced lung injury.  
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Figure 25. GM-CSF-deficiency is associated with decreased AEC II proliferation after LPS-
induced lung injury. (A) Flow cytometric quantification of the proliferating proportion of AEC II in 
LPS-treated wt (white bars), GM-/- (grey bars) and SPC-GM (black bars). Bar graphs represent the 
percentage of Ki-67+ of total AEC II (CD45-/pro-SP-C+) in lung homogenates from n=3 mice per 
group. Values are given as means ± SD. (B) Representative immunofluorescence staining of lung 
cryosections obtained from untreated or 96 h LPS-treated wt, GM-/- and SPC-GM mice. Arrows depict 
pro-SP-C (red) positive cells expressing Ki-67 (green); magnification x20; Iso IgG, isotype IgG 
control; untr, untreated. *p<0.05, **p<0.01.  
 
 
Figure 26. Reduction of total AEC numbers after LPS-induced lung injury is due to loss of AEC 
II but not of AEC I. The proportions and total AEC numbers in lung homogenates of untreated and 
LPS-treated wt (white bars), GM-/- (grey bars) and SPC-GM (black bars) mice were determined by 
flow cytometry. (A) AEC II proportion of lung homogenate cells; bar graphs represent the percentage 
of pro-SP-C+ cells in lung homogenates from n=3 mice per group. (B) Flow-cytometric analysis of 
AEC I (T1-α+) percentage in lung homogenates of untreated and LPS-treated mice. (C) Total AEC 
(AEC II + AEC I) numbers in lung homogenates before and after 96 h of LPS. Total AEC numbers 
were calculated from the respective AEC II and AEC I percentages and total cell numbers of 
homogenates. Data is given as means ± SD from n=3 mice per group. Values are given as means ± SD. 
**p<0.01, ***p<0.001. 
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Given that epithelial GM-CSF contributed to AEC II proliferation in the resolution phase of 
LPS-induced lung injury, the contribution of epithelial GM-CSF in the restoration of alveolar 
barrier function in the LPS-model was subsequently investigated. Therefore, alveolar leakage 
was assessed in LPS-injured mice of the three treatment groups in the time course after LPS 
administration. A prominent induction of alveolar leakage in wt and SPC-GM mice after 6 h 
of LPS instillation was detected, which was found to be reduced to baseline levels after 96 h. 
GM-/- mice, however, showed a sustained increase of alveolar barrier dysfunction until 240 h 
post LPS administration, suggesting that GM-CSF, by enhancing AEC II proliferation and 
renewal, contributes to restoration of alveolar barrier function severely disturbed in LPS-
induced acute lung injury (Fig. 27). 
 
Figure 27. Alveolar leakage in wt (white bars), GM-/- (grey bars) and SPC-GM (black bars) at 
various time intervals post LPS administration. Data is given as the ratio between FITC 
fluorescence in BALF and serum (arbitrary units, AU). Data is presented as means ± SD from at least 
n=3 animals per group; *p<0.05, **p<0.01. 
 
To investigate whether the observed influence of pro-inflammatory activated AMφ in alveolar 
epithelial repair in the LPS model also occurred in Gram-negative pneumonia, wt mice were 
intratracheally treated with K. pneumoniae for the indicated time intervals and total BALF 
leukocyte numbers were analysed and differential counts performed. As demonstrated in Fig. 
28, K. pneumoniae infection in wt mice resulted in a similar, yet more severe inflammatory 
reaction compared to the LPS model, characterised by a high leukocyte influx 48 hours after 
infection (hpi), correlating with the neutrophil peak following infection. Similar to the 
findings in LPS-challenged mice, K. pneumoniae infection in wt mice resulted in a prominent 
production of GM-CSF and TNF-α at the early onset of inflammation (Fig. 29).  
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Figure 28. Quantification of total BALF leukocytes and leukocyte-subpopulations after K. 
pneumoniae infection in wt mice. BALF was performed at different time intervals post intratracheal 
infection with 25x104 CFU/mouse. Total BALF cell counts were determined and leukocyte differential 
counts were obtained from Pappenheim-stained cytocentrifuge preparations. Data is given as total cells 
and represents means ± SD from n=3 animals per group.  
 
 
Figure 29. TNF-α and GM-CSF levels in BALF from K. pneumoniae infected wt mice. Data is 
presented as means ± SD from n=3 mice per group; *p<0.05, **p<0.01.  
 
Resembling the LPS-model, the cytokine release correlated with an increased proliferation of 
AEC II at 72 h post K. pneumoniae infection, which thereafter gradually decreased until 192 
hpi (Fig. 30A). Furthermore, the AEC II proportion in lung homogenates decreased at 72 hpi 
most likely due to AEC II injury, but was steadily replenished until 192 hpi (Fig. 30B). In 
addition, intraalveolar TNF-α neutralisation 72 hpi resulted in a remarkable decrease of AEC 
II proliferation, as well as decrease of the AEC II proportion in lung homogenates (Fig. 30C). 
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Figure 30. Alveolar repair after K. pneumoniae infection is associated with TNF-α-dependent 
AEC II proliferation. (A) At the indicated time points the proliferating proportion of AEC II was 
determined in K. pneumoniae infected mice. Bar graphs represent the percentage of Ki67+ of total 
AEC II (pro SP-C+/CD45-) in lung homogenates from n=3 mice per group. (B) AEC II proportion (pro 
SP-C+) of lung homogenate cells from lavaged lungs of n=3 mice per group. (C) FACS quantification 
of proliferating AEC II (left panel) and AEC II proportion in lung homogenates (right panel) of wt 
mice (n=3) infected intratracheally with K. pneumoniae and treated with either a-TNF-α or respective 
IgG antibodies, for 72 h. Values are means ± SD. *p<0.05, ***p<0.001. 
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5. Discussion 
Damage of the endo-epithelial barrier is the major hallmark of acute lung injury upon 
bacterial infection, associated with oedema formation, alveolar flooding, impaired fluid 
clearance and gas exchange. Hence, to restore the normal lung function, alveolar repair 
processes are ultimately initiated (34). Resident alveolar macrophages have been assigned a 
contributing role in epithelial repair, closely associated with the transition of the pro-
inflammatory into the anti-inflammatory macrophage phenotype (62, 94). In the current thesis 
the potential of early activated, pro-inflammatory resident alveolar macrophages to influence 
epithelial repair processes was investigated. Moreover, the hypothesis that pro-inflammatory 
resident alveolar macrophages may contribute to effective epithelial repair after LPS- and K. 
pneumoniae induced lung injury was tested. Hence, in vitro experiments revealed that alveolar 
epithelial cells co-cultured with LPS-stimulated resident alveolar macrophages express 
significantly higher amounts of growth factors, particularly of GM-CSF. Macrophage TNF-α 
released upon LPS stimulation was identified as a mediator inducing GM-CSF expression in 
epithelial cells, which in turn elicited autocrine proliferative signalling in type II alveolar 
epithelial cells. Genetic deletion of GM-CSF resulted in absence of macrophage-induced 
epithelial cell proliferation. Similarly, in vivo TNF-α neutralization after LPS-induced lung 
injury impaired epithelial proliferation. Furthermore, GM-CSF-deficient mice displayed 
reduced AEC II proliferation and sustained alveolar leakage after LPS challenge. Similarly, K. 
pneumoniae-induced lung injury was associated with early release of TNF-α and GM-CSF, 
and subsequent TNF-α-dependent AEC II proliferation during the alveolar repair phase. 
Altogether, these data reveal that alveolar repair processes are initiated early in the 
inflammatory course of pathogen-induced acute lung injury, and are mediated by macrophage 
TNF-α and epithelial GM-CSF (Fig. 31). 
 
Figure 31. Proposed model of AMφ/AEC cross-talk in alveolar barrier repair. TNF-α released 
from LPS-activated AMφ induces expression of GM-CSF in alveolar epithelial cells, which in turn 
mediates AEC II proliferation and barrier renewal via a STAT5-dependent autocrine signalling loop. 
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5.1. The contribution of pro-inflammatory resident alveolar macrophages 
to epithelial repair 
Alveolar macrophages at the site of inflammation have been demonstrated to acquire an anti-
inflammatory phenotype driven by lipid mediator-induced signalling, and hence to actively 
promote the resolution of inflammation. These signalling events trigger increased macrophage 
phagocytosis activity, decreased neutrophil migration, diminished superoxide production by 
neutrophils and iNOS by macrophages, as well as reduced adhesion molecule activation and 
gene expression (102). Additionally, the decreased NF-қB activation in alveolar macrophages 
results in a profile switch of released cytokines, from pro- to anti-inflammatory mediators 
such as TGF-ß and IL-10 (62). Moreover, previous reports demonstrated that anti-
inflammatory AMφ directly release epithelial mitogens, thereby inducing alveolar epithelial 
cell proliferation (60, 61, 103). The current data add to the aforementioned concept of 
macrophage-epithelial cross-talk during alveolar reparative events. Interestingly, the present 
thesis evidences that LPS-activated AMφ, via release of the pro-inflammatory cytokine TNF-
α, have the potential to stimulate AEC themselves to produce epithelial growth factors, 
thereby enhancing alveolar repair processes. In contrast, LPS-activated AMφ did not express 
any of the epithelial mitogens analysed, implying that pro-inflammatory AMφ most likely 
indirectly initiate epithelial repair signalling via soluble mediators. Hence, this thesis provided 
data demonstrating that alveolar epithelial cell proliferation is dependent on macrophage 
TNF-α in vitro and in vivo. Of note, our group recently showed that “exudate macrophages” 
(ExMφ) massively recruited during influenza virus pneumonia may induce alveolar epithelial 
apoptosis via TNF-related apoptosis inducing ligand (TRAIL), thereby contributing to loss of 
barrier function (87). In contrast, in the LPS-model with very limited ExMφ accumulation in 
the airspaces (0.0565 ± 0.02x106 after 96 h), opposing reparative effects of AMφ towards the 
alveolar epithelium were observed. Such a divergent role of lung macrophages emerges most 
likely from the macrophage phenotype analysed (resident vs. recruited) and the different 
inflammatory models applied. 
TNF-α is an early pro-inflammatory cytokine, known to be primarily released from activated 
resident alveolar macrophages and to stimulate alveolar cell populations for chemokine 
release and adhesion molecule expression, thereby initiating and maintaining innate host 
defence (43). Besides its predominant pro-inflammatory, tissue-destructive role, several 
reports suggested TNF-α to exert resolution- and repair-enhancing effects by different 
mechanisms. In this line, TNF-α was shown to induce urokinase-type plasminogen activator 
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in alveolar epithelial cells followed by lysis of alveolar fibrin and resolution of inflammation 
(104). Similar to the data presented in the current thesis, TNF-α was described as a mediator 
of the proliferation of gastric epithelium and human retinal pigment epithelial cells (65, 105). 
Moreover, TNF-α has been previously reported to induce expression of GM-CSF in 
endothelial cells and fibroblasts via activation and nuclear translocation of the transcription 
factor NF-κB (67, 106). Furthermore, NF-κB was shown to be nuclearly translocated upon 
TNF receptor binding in human lung epithelial cells (107). Besides its widely known pro-
inflammatory function, NFκB has recently been associated with signalling events mediating 
the resolution of inflammation, particularly via TGF-ß1 production (108), thereby 
strengthening the concept of a dichotomic role of TNF-α induced signalling events in acute 
inflammation.  
Taken together, the data presented in this thesis suggest that epithelial repair processes are 
implemented yet in the acute phase of alveolar inflammation and highlight the complexity of 
intercellular communication in lung inflammation and repair. 
 
5.2.  GM-CSF induced proliferative signalling in AEC  
The current thesis evidenced that TNF-α-mediated alveolar epithelial cell proliferation was 
largely mediated by the epithelial growth factor GM-CSF in vitro and in vivo. GM-CSF is a 
well known growth factor for phagocytes, but it also stimulates maturation of eosinophils, 
erythrocytes, megakaryocytes and dendritic cells. Apart from its effects on progenitor cells, 
GM-CSF improves host defence functions of mature hematopoietic cells, such as alveolar 
macrophages (68). More recent reports suggested a role of GM-CSF in the proliferation of 
alveolar type II cells (75, 77), however, the contribution of GM-CSF to epithelial repair and 
restoration of alveolar barrier function upon LPS-induced acute lung injury has not previously 
been addressed.  
Murine alveolar epithelial cells type II were shown to express the GM-CSF receptor 
α−subunit on lung tissue sections, whereas both α and ß subunits have been identified on 
freshly isolated rat AEC II (75, 76). Likewise, the data presented in this thesis demonstrated 
that both subunits are expressed in freshly isolated murine alveolar epithelial cells and 
downregulated during 5 days of in vitro trans-differentiation into type I-like cells, which was 
associated with pronounced proliferation of AEC at day 1, but not at day 3 of culture upon 
GM-CSF stimulation. Our group and others have observed that freshly isolated AEC in 
culture rapidly lose the type II phenotype (in less then 24 h), which is the major limit of the in 
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vitro studies with these cells (25, 109). In order to overcome this problem, a previously 
described in vitro model to preserve the AEC type II phenotype during culture was used (25). 
Accordingly, freshly isolated murine AEC were grown for up to 3 days on matrigel:collagen 
matrix . Under these conditions, differentiation was significantly diminished and the majority 
of the cells retained the “classical” type II phenotype. AEC cultured on matrigel:collagen 
matrix proliferated in response to GM-CSF and co-culture with LPS-stimulated AMφ revealed 
epithelial release of GM-CSF associated with increased AEC proliferation, thus confirming 
the concept that type II cells as opposed to type I cells represent the proliferating 
subpopulation (6). 
Furthermore additional evidence is provided that GM-CSF-induced alveolar epithelial cell 
proliferation was signalled by STAT5 phosphorylation resulting in increased expression of 
Cyclin D1. The JAK2-STAT5-Cyclin D1 pathway has been shown to be the underlying 
mechanism in prolactin stimulated proliferation of mammary epithelial cells (101). Of note, 
GM-CSF-mediated activation of cellular repair mechanisms has been similarly evidenced in 
different cell types such as endothelial cells and keratinocytes, resulting in increased 
proliferation and subsequently enhanced in vivo angiogenesis and wound healing (110, 111). 
Despite the fact that the JAK2-STAT5 axis has been evidenced to influence the cellular 
differentiation and phenotype (112), a non significant influence of GM-CSF signalling on the 
process of AEC II to I differentiation in vitro was identified. Interestingly, GM-CSF 
activation of JAK2 and STAT5 in human monocytes has been associated with induction of 
CCL2 production (99). In contrast, GM-CSF-stimulated AEC in the presented study did not 
reveal increased pro-inflammatory chemokine production. Additionally, GM-CSF was 
reported to activate MAPK and PI3K in myeloid cells (100), however activation of these 
pathways in alveolar epithelial cells was not detected.  
In summary, GM-CSF stimulation induced proliferative signalling in alveolar epithelial cells, 
most likely dependent on intracellular STAT5 activation and Cyclin D1 induction.  
 
5.3.  The role of the TNF-α – GM-CSF axis in alveolar repair following 
acute lung injury  
Given that the in vitro study revealed macrophage-TNF-α induced expression of GM-CSF in 
AEC, followed by an autocrine proliferative signalling, it was subsequently investigated 
whether a similar mechanism may drive the alveolar epithelial repair in vivo, in an LPS and K. 
pneumoniae model of acute lung injury. 
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In accordance with data obtained from a rat model (8), the current thesis demonstrated that 
alveolar repair processes in terms of epithelial cell type II proliferation were initiated 4 days 
after LPS instillation, when alveolar inflammation decreased virtually to baseline levels. In 
contrast, a significantly reduced epithelial proliferation and sustained loss of barrier function 
throughout day 10 post LPS challenge was observed in GM-CSF-deficient mice in vivo, 
confirming the in vitro findings with GM-CSF-deficient alveolar epithelial cells lacking a 
TNF-α-induced proliferative response. Interestingly, AEC II proliferation after LPS challenge 
was completely rescued in SPC-GM mice, and epithelial GM-CSF release was widely 
reduced upon alveolar TNF-α neutralisation in wt mice in vivo. These data clearly indicate 
that the alveolar epithelium itself is the primary source of GM-CSF, which is in turn released 
in the presence of TNF-α, emphasizing the central role of alveolar type II epithelial cells in 
perpetuating self-renewal and barrier restoration once they have received an initial 
macrophage signal. 
Interestingly, the neutrophilic response in GM-/- mice was more pronounced at 6 to 24 hours 
after LPS treatment as compared to wt mice, correlating with the previous findings that GM-/- 
neutrophils are fully functional and their recruitment at the onset of inflammation is 
successfully (over-)compensated (113). Moreover, Paine et al evidenced a decreased activity 
of GM-/- alveolar macrophages characterised with impaired in vitro phagocytosis and 
decreased TNF-α release, which in vivo resulted in increased susceptibility to Pneumocystis 
carinii infection and increased inflammation, compared to wild-type mice (114). Therefore, it 
was assumed that the prolonged alveolar neutrophil presence observed at 96 and 148 h post 
LPS instillation is most likely due to alveolar macrophage dysfunction in GM-/- mice with 
decreased phagocytosis of apoptotic neutrophils and delayed resolution of alveolar 
inflammation. 
Alveolar barrier disruption has been described as a neutrophil-mediated damage resulting in 
paracellular permeability, which in turn leads to leakage of fluids that characterize the acute 
lung injury (ALI). At least three distinct mechanisms are involved in opening the epithelium: 
(1) highly regulated disassembly and reassembly of tight junctions, (2) mechanical force 
resulting in epithelial wounds, especially during high tidal volume ventilation, and (3) 
degradative effects of neutrophil derived mediators (pro-apoptotic factors, proteases or 
reactive oxygen/nitrogen species) (115, 116). Importantly, in the presented thesis, sustained 
lung leakage in GM-/- mice was observed beyond the neutrophil decrease (240 h) indicating 
that the inflammatory injured epithelial barrier lacked an adequate proliferation stimulus in 
absence of GM-CSF. In contrast, neutrophil clearance was enhanced in GM-CSF-
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overexpressing (SPC-GM) mice, most likely correlated to increased GM-CSF amounts in 
BALF and subsequently enhanced macrophage phagocytotic function. SPC-GM mice also 
displayed faster alveolar neutrophilic influx than wt mice, probably due to the chemotactic 
activity of GM-CSF taking effects when present in excessive amounts (117). 
Alveolar TNF-α levels peaked at 6 h post LPS instillation in all treatment groups, however 
they were significantly increased in SPC-GM mice and decreased in GM-CSF-deficient 
compared to wt mice, indicating that, apart from its reparative effects on epithelial cells, GM-
CSF may enhance macrophage host defence functions. A recent report suggested that GM-
CSF regulates TLR4-dependent signalling events such as TNF-α release from LPS-treated 
alveolar macrophages via activation of the transcription factor PU.1 (118). Therefore, GM-
CSF might promote alveolar repair upon bacterial pneumonia in two ways: first, due to its 
direct proliferative effects on alveolar epithelium, and second, by enhancing macrophage 
TNF-α release, which in turn mediates further epithelial GM-CSF expression. TNF-α 
inhibition as therapeutic strategy to attenuate acute or chronic pulmonary inflammation might 
therefore hold the risk of insufficient tissue repair.  
Although recognition of LPS by TLR4 is an essential step in initiating an effective immune 
response in gram-negative pneumonia (119, 120), LPS instillation alone does not fully reflect 
the complex events observed in bacterial pneumonia. Hence, a K. pneumoniae pneumonia 
model was used to evaluate the role of macrophage – epithelial cross-talk during the alveolar 
repair phase after acute gram-negative pneumonia. The presented data confirm that 
macrophage TNF-α is indeed a crucial mediator initiating AEC II proliferation during K. 
pneumoniae infection. 
Taken together, the current thesis demonstrates that epithelial repair processes may be primed 
already in the pro-inflammatory phase of acute lung injury. Novel evidence is provided for the 
key role of macrophage TNF-α inducing alveolar repair via epithelial GM-CSF. Thus, 
detection of distinct intercellular cross-talk mechanisms mediating tissue repair in the course 
of severe pneumonia may identify therapeutic targets allowing timed and compartment-
specific intervention strategies promoting regeneration of the injured alveolar barrier. 
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6. Summary 
Bacterial invasion of the alveolar air space is followed by the fast, tightly regulated immune 
response facilitating a successful pathogen clearance. Upon pathogen recognition activated 
resident alveolar macrophages (AMφ) early release pro-inflammatory cytokines, stimulating 
neighbouring alveolar cells to produce chemokines which in turn mediate the infiltration of 
neutrophils, exudate macrophages and lymphocytes. The following inflammatory reaction and 
the pathogen itself leave a damaged alveolar barrier associated with pulmonary oedema and 
impaired gas exchange. Consequently, epithelial repair processes are initiated to restore the 
normal lung homeostasis. During the later phase of infection AMφ have been shown to 
acquire an anti-inflammatory phenotype thereby enhancing alveolar repair processes. 
However, the potential of early activated, pro-inflammatory AMφ to influence epithelial 
repair remains largely elusive. Therefore, in the present thesis it was investigated whether 
activated AMφ contribute to alveolar epithelial repair upon LPS challenge in vitro and in vivo, 
as well as in K. pneumoniae pneumonia, and the molecular interaction pathways involved 
were analysed. The cross-talk between resident alveolar macrophages and alveolar epithelial 
cells during alveolar repair was assessed in an in vitro co-culture system and an in vivo model 
of LPS-induced acute lung injury. Gene expression and protein analysis showed that LPS-
activated alveolar macrophages stimulated alveolar epithelial cells (AEC) to express growth 
factors, particularly GM-CSF upon co-culture. Antibody neutralization experiments revealed 
epithelial GM-CSF expression to be macrophage TNF-α dependent. GM-CSF elicited 
proliferative signalling in alveolar epithelial cells via autocrine activation of the transcription 
factor STAT 5 and Cyclin D1 expression. Notably, macrophage TNF-α induced epithelial 
proliferation in wild-type but not in GM-CSF-deficient alveolar epithelial cells as shown by 
[3H]-thymidine incorporation and cell counting. Matrigel:collagen AEC culture preserving the 
type II phenotype in vitro supported the concept that the proliferative response to GM-CSF is 
related to the type II AEC phenotype. Moreover, intra-alveolar TNF-α neutralization impaired 
alveolar epithelial type II cell proliferation in LPS-injured mice in vivo, as investigated by 
flow cytometric Ki67 and immunofluorescence staining of lung sections. Additionally, GM-
CSF-deficient mice displayed reduced AEC II proliferation and sustained alveolar barrier 
dysfunction upon LPS treatment compared to wild-type and SPC-GM mice (overexpressing 
GM-CSF in AEC II in a GM-CSF-deficient background). Similarly, K. pneumoniae lung 
infection confirmed the findings in the LPS-model and resulted in early release of macrophage 
Summary  56 
TNF-α and epithelial GM-CSF, as well as subsequent TNF-α-dependent AEC II proliferation 
during alveolar repair events. 
Collectively, these findings indicate that TNF-α released from activated resident alveolar 
macrophages induces epithelial GM-CSF expression, which in turn initiates alveolar epithelial 
type II cell proliferation and thus contributes to restore alveolar barrier function. 
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7. Zusammenfassung 
Die bakterielle Infektion des Alveolarraumes ist regelhaft von einer schnellen, streng 
koordinierten Immunantwort gefolgt, deren Ziel die rasche Elimination des Erregers ist. Nach 
der Erkennung des Erregers über spezielle Pathogen-Rezeptoren setzen Alveolarmakrophagen 
(AMФ) pro-inflammatorische Zytokine frei und stimulieren benachbarte Parenchymzellen zur 
Produktion von Chemokinen, welche letztendlich die Chemotaxis neutrophiler Granulozyten, 
von Exudatmakrophagen und Lymphozyten vermitteln. Diese Immunreaktion, aber auch die 
Infektion selbst, führen zu einer Destruktion der alveolären Barriere mit konsekutivem 
alveolärem Ödem und eingeschränktem Gasaustausch. In der Folge werden alveoläre 
Reparaturprozesse in Gang gesetzt, um die Organfunktion wieder herzustellen. 
Alveolarmakrophagen aquirieren in der Spätphase der Entzündung einen anti-
inflammatorischen Phänotyp und können solche Reparaturprozesse in Gang setzen. Jedoch 
war das Reparaturpotenzial früh aktivierter, pro-inflammatorischer Alveolarmakrophagen bis 
dato ungeklärt. In der vorliegenden Arbeit wurde deshalb untersucht, ob früh-inflammatorisch 
aktivierte residente Alveolarmakrophagen zur alveolarepithelialen Reparatur nach LPS-
Applikation in vitro und in vivo und im Klebsiella-Pneumonie-Modell beitragen und welche 
die zugrunde liegenden molekularen Mechanismen sind. Es wurden die Mediatoren des 
Cross-talk zwischen Alveolarmakrophagen und Alveolarepithel in der alveolarepithelialen 
Reparatur in einem in vitro Ko-Kulturmodell und im Mausmodell der LPS-induzierten Acute 
Lung Injury ermittelt. Genexpressions- und Proteinanalysen zeigten hierbei, dass LPS-
aktivierte Alveolarmakrophagen in der Ko-Kultur Alveolarepithelzellen zur Freisetzung 
epithelialer Wachstumsfaktoren, insbesondere von GM-CSF, stimulieren. 
Neutralisationsexperimente zeigten, dass die epitheliale GM-CSF Expression abhängig war 
von Makrophagen-sezerniertem TNF-α. GM-CSF induzierte autokrin eine STAT5-Cyclin 
D1-vermittelte proliferative Signalkaskade in Alveolarepithelzellen. Interessanterweise konnte 
mittels [3H]-Thymidin-Einbau und Zellzählung gezeigt werden, dass TNF-α eine epitheliale 
Proliferation in Wildtyp-, nicht jedoch in GM-CSF-defizienten Alveolarepithelzellen 
induziert. Ähnliche Experimente mit Alveolarepithelzellen, die auf einer Matrigel:Collagen-
Matrix kultiviert wurden und dabei einen Phänotyp II (AEC II) behielten, zeigten, dass diese 
GM-CSF-vermittelte Proliferationsantwort an den Phänotyp II gekoppelt war. Darüberhinaus 
konnte im LPS-Mausmodell gezeigt werden, dass die intraalveoläre Neutralisation von TNF-
α die Proliferation von Typ II Alveolarepithelzellen in vivo, gemessen anhand der Ki-67 
Expression im FACS und in der Immunfluoreszenz, deutlich reduzierte. Zusätzlich zeigten 
GM-CSF-defiziente Mäuse eine eingeschränkte Alveolarepithelzellproliferation und eine 
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deutlich prolongierte Dysfunktion der alveolären Barriere nach intratrachealer LPS-Gabe 
verglichen mit Wildtyp- oder SPC-GM-Mäusen (mit Überexpression von GM-CSF im 
Alveolarepithel, generiert in GM-CSF-defizienten Mäusen). Im Klebsiella-Pneumoniemodell 
konnten diese Mechanismen bestätigt werden. Zusammenfassend konnte gezeigt werden, dass 
TNF-α, welches von LPS-aktivierten residenten Alveolarmakrophagen freigesetzt wird, eine 
alveolarepitheliale GM-CSF-Expression induziert. GM-CSF wiederum initiiert über eine 
autokrine Signalkaskade die Proliferation von Typ II Alveolarepithelzellen und trägt somit 
wesentlich zur Erneuerung und Funktionalität der alveolarepithelialen Barriere bei. 
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9. Supplements 
9.1.  Materials and source of supply 
[3H]-thymidine  GE Healthcare, Germany 
5x 1st strand buffer Invitrogen, UK 
Abbocath Abbott, Germany 
Acrylamide solution, Rotiphorese Gel 30 Roth, Germany 
Agarose Invitrogen, UK 
Agarose, low-melting Sigma-Aldrich, Germany 
a-hamster-AlexaFluor 488 IgG Invitrogen, UK 
a-hamster-AlexaFluor 647 IgG Invitrogen, UK 
a-human Ki-67 PE mAb  BD Pharmingen, Germany 
a-human pro-SP-C Ab Chemicon International, UK 
Ammonium persulfate (APS) Promega, Germany 
a-mouse Ki-67 mAb Dako, Germany 
a-mouse T1-α/podoplanin/gp36 mAb Abcam, UK 
a-mouse TNF-α mAb R&D, Germany 
a-mouse widespread cytokeratin Ab Dako, Germany 
Antibiotics (Pen/Strep) PAA Laboratories, Austria 
a-pSTAT5 Ab Cell signalling, Germany 
a-rabbit AlexaFluor 488 IgG Invitrogen, UK 
a-rabbit AlexaFluor 555 IgG Invitrogen, UK 
a-rabbit AlexaFluor 647 IgG Invitrogen, UK 
a-rabbit IgG horseradish peroxidase Pierce, USA 
a-rat AlexaFluor 488 IgG Invitrogen, UK 
a-STAT5 Ab Cell signalling, Germany 
Autoradiograph (Amersham Hyperfilm ECL, GE 
Healthcare, Germany) 
Biotinylated a-mouse CD16/32 mAb BD Pharmingen, Germany 
Biotinylated a-mouse CD31 mAb BD Pharmingen, Germany 
Biotinylated a-mouse CD45 mAb BD Pharmingen, Germany 
Bovine serum albumin (BSA) Sigma-Aldrich, Germany 
Bromophenol blue Sigma-Aldrich, Germany 
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Collagenase A Roche, USA 
DC protein assay Bio-Rad, Germany 
DifcoTM Skim Milk BD Pharmingen, Germany 
Dispase BD Biosciences, Germany 
Dithiothreitol (DTT) Invitrogen, UK 
DNAse Serva, Germany 
dNTPs Roche, USA 
Dulbecco’s modified eagle medium (DMEM) PAA Laboratories, Austria 
E.coli lipopolysaccharide (0111:B4) Calbiochem, Germany 
ECL Plus Western Blotting Detection System Amersham Biosciences, UK 
EDTA Biochrom, Germany 
ELISA kits R&D Systems, Germany 
Ethanol Riedel-de-Hän, Germany 
Ethidium bromide solution Carl Roth, Germany 
Fc-Block BD Pharmingen, Germany 
Fetal Calf Serum (FCS)  PAA Laboratories, Austria 
FITC-Albumin Sigma-Aldrich, Germany 
Glycine Sigma-Aldrich, Germany 
Goat IgG R&D Systems, Germany 
Hamster IgG BD Pharmingen, Germany 
Hank’S buffered saline solution (HBSS) PAA laboratories, Austria 
HEPES buffer Invitrogen, UK 
Hydrochloric acid (HCl) Merck, Germany 
Isoflurane (1-chloro-2,2,2-trifluoroethly 
difluoromethyl ether) 
Abbott, Germany 
Ketavet (Ketamine hydrochloride) Pharmacia & Upjohn, Germany 
Matrigel BD Biosciences, Germany 
McConkey agar plates Oxoid GmbH, Germany 
Methanol  Fluka, Germany 
M-MLV reverse transcriptase Invitrogen, UK 
Mounting medium with DAPI (Vectashield) Vector Laboratories, USA 
Mouse IgG1 PE BD Pharmingen, Germany 
N,N,N',N'-tetramethyl-ethane-1.2-diamine 
(TEMED) 
Sigma-Aldrich, Germany 
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Pam3-Cys-Ser-Lys-Lys-Lys-Lys-OH 
(Pam3CSK4) 
EMC Microcollections, Germany 
Pappenheim staining solutions 
(May-Grünwald/Giemsa) 
Merck, Germany 
Paraformaldehyde (PFA) Sigma-Aldrich, Germany 
Phosphate buffered saline (PBS) PAA Laboratories, Austria 
Platinum Taq DNA polymerase Invitrogen, UK 
PlatinumSYBRGreen I qPCR SuperMix-
UDG 
Invitrogen, UK 
Polyvinylidene difluoride (PVDF) membranes  Micron Separations, USA 
Precision Plus ProteinTM Standards Bio-Rad, USA 
Protease inhibitor cocktail Roche, Germany 
Rabbit IgG Chemicon, Upstate 
Random hexamers Boehringer, Germany 
Rat Collagen R&D Systems, Germany 
Rat IgG2a BD Pharmingen, Germany 
Recombinant murine TNF-α R&D Systems, Germany 
RNA isolation kit Peqlab, Germany 
RNase away Molecular bioproducts, USA 
RNase inhibitor Promega, USA 
RNeasy Mini Kit Qiagen, Germany 
Rompun (Xylazine hydrochloride)  Bayer,Germany 
RPMI 1640 medium PAA laboratories, Austria 
Saponin Calbiochem, Germany 
Sodium chloride Braun, Germany 
Sodium dodecyl sulphate (SDS) Sigma-Aldrich, Germany 
Sodium ortho vanadate Sigma-Aldrich, Germany 
ß-mercaptoethanol Sigma-Aldrich, Germany 
Streptavidin linked APC-Cy7 BD Pharmingen, Germany 
Streptavidin-linked Dynabeads Paramagnetic 
particles 
Invitrogen, UK 
TissueTek OCT Sakura Finetek, USA 
Todd-Hewit Broth BD Biosciences, Germany 
Tris Carl Roth, Germany 
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Trypan blue Sigma-Aldrich, Germany 
Trypsin PAA laboratories, Austria 
Tween 20 Sigma-Aldrich, Germany 
Wildtype mice (C57/Bl6) Charles River, Germany 
 
9.2.  Technical equipment and manufacturer 
ABI PRISM 7900HT Sequence detector Applied Biosystems, USA 
Agilent Bioanalyser 2100 Agilent Tech.,Germany 
BioDocAnalyse video system Whatman – Biometra, Germany 
Cell culture incubator Heraeus, Germany 
Cell-culture plates/transwells: 24 wells BD Labware, USA 
Cell-culture plates: 48 wells Greiner Bio-One, Germany 
Chamber slides (8 well) Permanox 
Lab-Tek Thermofisher Scientific, 
Denmark 
Cytospin Cytocentrifuge Thermo Scientific, Germany 
Developing machine, Curix 60 Agfa, Germany 
Digital Imaging Software Leica, Germany 
Electrophoresis apparatus Keutz, Germany 
ELISA reader Molecular Devices, Germany 
Eppendorf tubes (0,6ml/1.5ml/2 ml) Eppendorf, Germany 
FACSCanto BD, Germany 
FACSDiva Software Package BD, Germany 
Filter tip Greiner bio-one, Germany 
Filter units  Millipore, USA 
Fluorescence spectrophotometer 
FL 880 microplate fluorescence reader, 
Bio-Tek Instruments, France  
Light/Fluorescence microscope 
Leica DM 2000 Light Microscope, 
Germany 
Mini Protean 3 cell Bio-Rad, USA 
Mini spin centrifuge Heraeus, Germany 
Mini Trans Blot Bio-Rad, USA 
Multifuge centrifuge, 1S-R Heraeus, Germany 
NanoDrop ND-1000 Nano Technologies, USA 
Supplements  71 
PCR tubes (0.2 ml) Applied Biosystems, USA 
peqSTAR 96 Universal Gradient Cycler Peqlab, Germany 
Pipetmans: P10, P20, P100, P200, P1000  Gilson, France 
Pipette tip BD, Germany 
Power supply Biometra, Germany 
Serological pipette: 5, 10, 25, 50 ml  Falcon, USA 
Stereomicroscope Leica MS5, Germany 
Test tube thermostat Roth, Germany 
Test tubes :15, 50 ml Greiner Bio-One, Germany 
Vortex machine Scientific Industries, Germany 
Supplements  72 
9.3.  List of primers for real-time RT-PCR 
Gene Name Forward primer sequence 
(5’ → 3’) 
Reverse primer sequence 
(5’ → 3’) 
C-EBPα AAAGCCAAGAAGTCGGTGGAC CTTTATCTCGGCTCTTGCGC 
Cyclin D1 ACAGCTGCTTCGGGTCTGAGTTC GGGAGCCACCTTCTTCTTTCA 
FGF2 AGCGACCCACACGTCAAACT CGTCCATCTTCCTTCATAGCAAG 
GABRP GCGCCTTGCTCAGTACACAA ACGTTCCTCCGAAGCTCAAAT 
GM-CSF GAAGCATGTAGAGGCCATCA GAATATCTTCAGGCGGGTCT 
GM-CSFRß TCCTTCCGGCCAGATAGTGA GGAGCTGATGCTGACGTTCTT 
GM-CSFRα GCGACACGAGGATGAAGCA CACTGCATACAGGAGCGCA 
HMBS GGTACAAGGCTTTCAGCATCGC ATGTCCGGTAACGGCGGC 
IGF-1 AGCTGGTGGATGCTCTTCAGTT GGTGCCCTCCGAATGCT 
KGF TCGCACCCAGTGGTACCTG ACTGCCACGGTCCTGATTTC 
PDGFa ATGCCAACCTCAGGAGAGAT TGTCAGAAGCAGGTTCCTTG 
PDGFb CTGCTAGCGTCTGGTCA CATCAAAGGAGCGGATGGAG 
PDGFc AATTGTGCCTGTTGTCTCCA TATGCAATCCCTTGACTCCA 
PDGFd CCAGGACGGTCATTTACGAGA GCGCTTCACCTCCACACAT 
pro-SP-C TCCTGATGGAGAGTCCACCG CAGAGCCCCTACAATCACCAC 
T1-α ACAGGTGCTACTGGAGGGCTT TCCTCTAAGGGAGGCTTCGTC 
TGF-α GGCTGCAGTGGTGTCTCA AGCCACCACAGCCAGGA 
TNFR1 TTCTGAGAGAAAGTGAGTGCGT GGTTTGTGACATTTGCAAGC 
TNFR2 AGGTCTGGAACCAGTTTCGT CACACTCGGTTCTGCTGTTT 
VEGF TGTACCTCCACCATGCCAAGT AATCGGACGGCAGTAGCTTC 
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